



(11)

EP 2 272 975 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
22.04.2015 Bulletin 2015/17

(51) Int Cl.:
C12Q 1/68 (2006.01) **C12N 15/09** (2006.01)
G01N 33/53 (2006.01)

(21) Application number: **09725639.0**

(86) International application number:
PCT/JP2009/056785

(22) Date of filing: **25.03.2009**

(87) International publication number:
WO 2009/119891 (01.10.2009 Gazette 2009/40)

(54) **METHOD FOR DETERMINATION OF DNA METHYLATION**

BESTIMMUNGSVERFAHREN FÜR DNA-METHYLIERUNG

PROCÉDÉ SERVANT À DÉTERMINER LA MÉTHYLATION DE L'ADN

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: **25.03.2008 JP 2008077967**

(43) Date of publication of application:
12.01.2011 Bulletin 2011/02

(73) Proprietor: **Sumitomo Chemical Company, Limited**
Tokyo 104-8260 (JP)

(72) Inventors:
• **TOMIGAHARA, Yoshitaka**
Toyonaka-shi
Osaka 560-0013 (JP)
• **SATOH, Hideo**
Ibaraki-shi
Osaka 567-0826 (JP)
• **TARUI, Hirokazu**
Toyonaka-shi
Osaka 561-0802 (JP)

(74) Representative: **Duckworth, Timothy John**
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(56) References cited:
WO-A1-2006/056478 WO-A1-2007/119518
WO-A1-2008/123537 WO-A1-2008/123538
WO-A2-2007/081791 US-A1- 2007 264 642

- **STERKY F ET AL: "Direct sequencing of bacterial artificial chromosomes (BACs) and prokaryotic genomes by biotin-capture PCR", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 60, no. 1-2, 5 February 1998 (1998-02-05), pages 119-129, XP004115549, ISSN: 0168-1656, DOI: DOI: 10.1016/S0168-1656(97)00196-X**
- **YU K TONG ET AL: "Detection of restriction enzyme-digested target DNA by PCR amplification using a stem-loop primer: application to the detection hypomethylated fetal DNA in maternal plasma", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 53, no. 11, 27 September 2007 (2007-09-27), pages 1906-1914, XP008132142, ISSN: 0009-9147, DOI: DOI:10.1373/CLINCHEM.2007.092619**
- **WEBER MICHAEL ET AL: "Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells.", NATURE GENETICS AUG 2005 LNKD- PUBMED:16007088, vol. 37, no. 8, August 2005 (2005-08), pages 853-862, XP002634922, ISSN: 1061-4036**
- **TONG, YU K. ET AL.: 'Detection of restriction enzyme-digested target DNA by PCR amplification using a stem-loop primer: application to the detection of hypomethylated fetal DNA in maternal plasma.' CLINICAL CHEMISTRY vol. 53, no. 11, 2007, pages 1906 - 1914, XP008132142**
- **SHIN SEIKAGAKU JIKKEN KOZA 2 KAKUSAN I -BUNRI SEISEI 1991, TOKYO, pages 169 - 172, 180, XP008150058**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 272 975 B1

- **YARMUSH, MARTIN L. ET AL.:**
'Immunoabsorption: strategies for antigen elution and production of reusable adsorbents.' **BIOTECHNOLOGY PROGRESS** vol. 8, no. 3, 1992, pages 168 - 178, XP008143270
- **HEISKANEN, MERVI ET AL.:** 'A novel method to quantitate methylation of specific genomic regions.' **PCR METHODS AND APPLICATIONS** vol. 4, no. 1, 1994, pages 26 - 30, XP000465079
- **ALLEN, R. CUTLER ET AL.:** 'Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.' **AMERICAN JOURNAL OF HUMAN GENETICS** vol. 51, no. 6, 1992, pages 1229 - 1239, XP008143271
- **NYGREN, ANDERS O. H. ET AL.:** 'Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences.' **NUCLEIC ACIDS RESEARCH** vol. 33, no. 14, 2005, pages E128 - 1-9, XP002596755
- **STERKY, FREDRIK ET AL.:** 'Direct sequencing of bacterial artificial chromosomes (BACs) and prokaryotic genomes by biotin-capture PCR.' **JOURNAL OF BIOTECHNOLOGY** vol. 60, no. 1-2, 1998, pages 119 - 129, XP004115549
- **SCHMIDT, PETER M. ET AL.:** 'Detection of activity of telomerase in tumor cells using fiber optical biosensors.' **BIOSENSORS & BIOELECTRONICS** vol. 17, no. 11-12, 2002, pages 1081 - 1087, XP001206070
- **BUCKLE, MALCOLM. ET AL.:** 'Real time measurements of elongation by a reverse transcriptase using surface plasmon resonance.' **PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA** vol. 93, no. 2, 1996, pages 889 - 894, XP002252240

Description

TECHNICAL FIELD

5 **[0001]** The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.

BACKGROUND ART

10 **[0002]** As a method for evaluating the methylation state of DNA in an objective DNA region in a genomic DNA contained in a biological specimen, for example, there is known a method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA (see, for example, Nucleic Acids Res., 1994, Aug 11; 22(15): 2990-7, and Proc. Natl. Acad. Sci. U.S.A., 1997, Mar 18; 94 (6) : 2284-9 for reference). In such a measuring method, first, it is necessary to extract DNA containing the objective DNA region from a DNA sample derived from a genomic DNA, and the extracting operation is complicated.

15 **[0003]** As a method of measuring the content of methylated DNA in an objective region of extracted DNA, for example, (1) a method of amplifying an objective region by subjecting the DNA to a chain reaction for DNA synthesis by DNA polymerase after modification of the DNA with a sulfite or the like (Polymerase Chain Reaction; hereinafter also referred to as PCR), and (2) a method of amplifying an objective region by subjecting the DNA to PCR after digestion of the DNA using a methylation sensitive restriction enzyme are known. Both of these methods require time and labor for DNA modification for detection of methylation, subsequent purification of the product, preparation of a reaction system for PCR, and checking of DNA amplification.

20 **[0004]** WO 2007/081791 relates to a method of detecting DNA methylation.

25 DISCLOSURE OF THE INVENTION

[0005] It is an object of the present invention to provide a method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA contained in a biological specimen in a simple and convenient manner.

[0006] That is, the present invention provides the following:

30 [1] A method of measuring the content of methylated DNA in a objective DNA region in a genomic DNA contained in a biological specimen, the objective DNA region having a recognition site of at least one kind of methylation sensitive restriction enzyme, comprising:

35 (1) First step of mixing a DNA sample comprising a single-stranded DNA (plus strand) containing the objective DNA region and a masking oligonucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of a recognition site for the at least one kind of methylation-sensitive restriction enzyme, thereby obtaining a partially single-stranded DNA in which the recognition site for the methylation-sensitive restriction enzyme forms double strand by complementary base-pairing with the masking oligonucleotide, followed by

40 digesting the DNA sample with the methylation-sensitive restriction enzyme wherein said enzyme digests a recognition site containing unmethylated cytosine and does not digest a recognition site containing methylated cytosine;

(2) Second step of obtaining methylated single-stranded DNA from the DNA sample that has been subjected to the digestion treatment in First step, by separating methylated double-stranded DNA contained in the DNA sample into methylated single-stranded DNA, and binding the methylated single-stranded DNA to an immobilized

45 methylated DNA antibody, thereby selecting the single-stranded DNA; and

(3) Third step of amplifying the methylated DNA in the objective DNA region from the selected single-stranded DNA to a detectable level by a polymerase chain reaction (PCR) and quantifying the amount of the amplified DNA.

50 [2] The method of [1], wherein the immobilized methylated DNA antibody is a methylcytosine antibody.

[3] The method of [1] or [2], wherein the biological specimen is blood, a bodily fluid, serum, plasma, a cell lysate, or a tissue lysate from a mammal.

[4] The method of any one of [1] to [3], wherein the DNA sample derived from the genomic DNA contained in the biological specimen is a DNA sample digested in advance with a restriction enzyme for which a recognition cleavage

55 site is not present in the objective DNA region of the genomic DNA, or a DNA sample purified in advance.

[5] The method of any one of [1] to [4], wherein the methylation-sensitive restriction enzyme is HhaI.

[6] The method of any one of [1] to [5], wherein a counter oligonucleotide is added when separating the methylated double-stranded DNA into the methylated single-stranded DNA in Second step.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007]

5 Fig. 1 shows results of 2% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the region comprising the nucleotide sequence of SEQ ID NO: 23 by PCR from a prepared sample in Example 1.

10 From the leftmost lane in the drawing, results in a DNA marker "MK", a sample "M" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, subjected to an "A" treatment, a sample "H" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, subjected to an "A" treatment, a sample "U" of a solution of an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, subjected to an "A" treatment, a sample "M" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, subjected to a "B" treatment, a sample "H" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, subjected to a "B" treatment, a sample "U" of a solution of an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, subjected to a "B" treatment, a sample "M" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, subjected to a "C" treatment, a sample "H" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, subjected to a "C" treatment, and a sample "U" of a solution of an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, subjected to a "C" treatment are shown.

25 Fig. 2 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 28 by PCR from a prepared sample in Example 2. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated DNA fragment MX (negative control), a solution "D" of an unmethylated DNA fragment X (negative control), a solution "MC" of a methylated DNA fragment MX, a solution "C" of an unmethylated DNA fragment X, a solution "MB" of a methylated DNA fragment MX, a solution "B" of an unmethylated DNA fragment X, a solution "MA" of a methylated DNA fragment MX, and a solution "A" of an unmethylated DNA fragment X are shown.

30 Fig. 3 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 45 by PCR from a prepared sample in Example 3. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated DNA fragment MY (negative control), a solution "D" of an unmethylated DNA fragment Y (negative control), a solution "MC" of a methylated DNA fragment MY, a solution "C" of an unmethylated DNA fragment X, a solution "MB" of a methylated DNA fragment MY, a solution "B" of an unmethylated DNA fragment Y, a solution "MA" of a methylated DNA fragment MA, and a solution "A" of an unmethylated DNA fragment Y are shown.

35 Fig. 4 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 53 by PCR from a prepared sample in Example 4. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated DNA fragment MT (negative control), a solution "D" of an unmethylated DNA fragment T (negative control), a solution "MC" of a methylated DNA fragment MT, a solution "C" of an unmethylated DNA fragment T, a solution "MB" of a methylated DNA fragment MT, a solution "B" of an unmethylated DNA fragment T, a solution "MA" of a methylated DNA fragment MT, and a solution "A" of an unmethylated DNA fragment T are shown.

40 Fig. 5 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 53 by PCR from a prepared sample in Example 5. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated yeast genomic DNA (negative control), a solution "D" of an unmethylated yeast genomic DNA (negative control), a solution "MC" of a methylated yeast genomic DNA, a solution "C" of an unmethylated yeast genomic DNA, a solution "MB" of a methylated yeast genomic DNA, a solution "B" of an unmethylated yeast genomic DNA, a solution "MA" of a methylated yeast genomic DNA, and a solution "A" of an unmethylated yeast genomic DNA are shown.

MODE FOR CARRYING OUT THE INVENTION

55 **[0008]** As the "biological specimen" in the present invention, for example, a cell lysate, a tissue lysate (here the term "tissue" is used in a broad sense including blood, lymph node and so on) or biological samples including bodily sections such as plasma, serum and lymph, bodily secretions (urine, milk and so on) and the like and a genomic DNA obtained by extracting these biological samples, in mammals can be recited. As a biological specimen, for example, samples

derived from microorganisms, viruses and the like can be recited, and in such a case, "a genomic DNA" in the present measuring method also means genomic DNA of microorganisms, viruses and the like.

[0009] When the specimen derived from a mammal is blood, use of the present measuring method in a regular health check or a simple examination is expected.

[0010] For obtaining a genomic DNA from a specimen derived from a mammal, for example, DNA may be extracted using a commercially available DNA extraction kit.

[0011] When blood is used as a specimen, plasma or serum is prepared from blood in accordance with a commonly used method, and using the prepared plasma or serum as a specimen, free DNA (including DNA derived from cancer cells such as gastric cancer cells) contained in the specimen is analyzed. This enables analysis of DNA derived from cancer cells such as gastric cancer cells while avoiding DNA derived from hemocytes, and improves the sensitivity of detection of cancer cells such as gastric cancer cells and a tissue containing the same.

[0012] The DNA sample derived from genomic DNA may be a DNA sample digested in advance with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region of the genomic DNA, or a DNA sample purified in advance by a prescribed method.

[0013] Usually, a gene (a genomic DNA) consists of four kinds of bases. In these bases, such a phenomenon is known that only cytosine is methylated, and such methylation modification of DNA is limited to cytosine in a nucleotide sequence represented by 5'-CG-3' (C represents cytosine, and G represents guanine. Hereinafter, the nucleotide sequence is also referred to as "CpG"). The site to be methylated in cytosine is its position 5. In DNA replication prior to cell division, only cytosine in "CpG" of a template chain is methylated immediately after replication, however, cytosine in "CpG" of a newly-generated strand is immediately methylated by the action of methyltransferase. Therefore, the methylation state of DNA will be passed to new two sets of DNA even after DNA replication. The term "methylated DNA" in the present invention means DNA occurring by such methylation modification.

[0014] The term "CpG pair" in the present invention means double-stranded oligonucleotide in which a nucleotide sequence represented by CpG and a CpG that is complement with this are base-paired.

[0015] The term "objective DNA region" (hereinafter, also referred to as an "objective region") used in the present invention means a DNA region for which presence or absence of methylation of cytosine included in the region is to be examined, and has a recognition site of at least one kind of methylation sensitive restriction enzyme. A DNA region containing at least one cytosine in a nucleotide sequence represented by CpG which is present in a nucleotide sequence of a promoter region, an untranslated region, or a translated region (coding region) of a useful protein gene such as Lysyl oxidase, HRAS-like suppressor, bA305P22.2.1, Gamma filamin, HAND1, Homologue of RIKEN 2210016F16, FLJ32130, PPARG angiopoietin-related protein, Thrombomodulin, p53-responsive gene 2, Fibrillin2, Neurofilament3, disintegrin and metalloproteinase domain 23, G protein-coupled receptor 7, G-protein coupled somatostatin and angiotensin-like peptide receptor, Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 and so on can be recited.

[0016] To be more specific, when the useful protein gene is a Lysyl oxidase gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Lysyl oxidase gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 1 (corresponding to a nucleotide sequence represented by base No. 16001 to 18661 in the nucleotide sequence described in Genbank Accession No. AF270645) can be recited. In the nucleotide sequence of SEQ ID NO: 1, ATG codon encoding methionine at amino terminal of Lysyl oxidase protein derived from human is represented in base No. 2031 to 2033, and a nucleotide sequence of the above exon 1 is represented in base No. 1957 to 2661. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 1, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 1 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1539, 1560, 1574, 1600, 1623, 1635, 1644, 1654, 1661, 1682, 1686, 1696, 1717, 1767, 1774, 1783, 1785, 1787, 1795 and so on in the nucleotide sequence of SEQ ID NO: 1 can be recited.

[0017] To be more specific, when the useful protein gene is a HRAS-like suppressor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HRAS-like suppressor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 2 (corresponding to a nucleotide sequence represented by base No. 172001 to 173953 in the nucleotide sequence described in Genbank Accession No. AC068162) can be recited. In the nucleotide sequence of SEQ ID NO: 2, the nucleotide sequence of exon 1 of a HRAS-like suppressor gene derived from human is represented in base No. 1743 to 1953. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 2, in particular, cytosine in CpG which is present in

EP 2 272 975 B1

a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 2 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1316, 1341, 1357, 1359, 1362, 1374, 1390, 1399, 1405, 1409, 1414, 1416, 1422, 1428, 1434, 1449, 1451, 1454, 1463, 1469, 1477, 1479, 1483, 1488, 1492, 1494, 1496, 1498, 1504, 1510, 1513, 1518, 1520 and so on in the nucleotide sequence of SEQ ID NO: 2 can be recited.

[0018] To be more specific, when the useful protein gene is a bA305P22.2.1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a bA305P22.2.1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 3 (corresponding to a nucleotide sequence represented by base No. 13001 to 13889 in the nucleotide sequence described in Genbank Accession No. AL121673) can be recited. In the nucleotide sequence of SEQ ID NO: 3, ATG codon encoding methionine at amino terminal of bA305P22.2.1 protein derived from human is represented in base No. 849 to 851, and a nucleotide sequence of the above exon 1 is represented in base No. 663 to 889. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 3, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 3 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 329, 335, 337, 351, 363, 373, 405, 424, 427, 446, 465, 472, 486 and so on in the nucleotide sequence of SEQ ID NO: 3 can be recited.

[0019] To be more specific, when the useful protein gene is a Gamma filamin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Gamma filamin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 4 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 63528 to 64390 in the nucleotide sequence described in Genbank Accession No. AC074373) can be recited. In the nucleotide sequence of SEQ ID NO: 4, ATG codon encoding methionine at amino terminal of Gamma filamin protein derived from human is represented in base No. 572 to 574, and a nucleotide sequence of the above exon 1 is represented in base No. 463 to 863. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 4, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 4 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 329, 333, 337, 350, 353, 360, 363, 370, 379, 382, 384, 409, 414, 419, 426, 432, 434, 445, 449, 459, 472, 474, 486, 490, 503, 505 and so on in the nucleotide sequence of SEQ ID NO: 4 can be recited.

[0020] To be more specific, when the useful protein gene is a HAND1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HAND1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 5 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 24303 to 26500 in the nucleotide sequence described in Genbank Accession No. AC026688) can be recited. In the nucleotide sequence of SEQ ID NO: 5, ATG codon encoding methionine at amino terminal of HAND1 protein derived from human is represented in base No. 1656 to 1658, and a nucleotide sequence of the above exon 1 is represented in base No. 1400 to 2198. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 5, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 5 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1153, 1160, 1178, 1187, 1193, 1218, 1232, 1266, 1272, 1292, 1305, 1307, 1316, 1356, 1377, 1399, 1401, 1422, 1434 and so on in the nucleotide sequence of SEQ ID NO: 5 can be recited.

[0021] To be more specific, when the useful protein gene is a Homologue of RIKEN 2210016F16 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Homologue of RIKEN 2210016F16 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 6 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 157056 to 159000 in the nucleotide sequence described in Genbank Accession No. AL354733) can be recited. In the nucleotide sequence of SEQ ID NO: 6, a nucleotide sequence of exon 1 of a Homologue of a RIKEN 2210016F16 gene derived from human is

represented in base No. 1392 to 1945. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 6, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 6 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1172, 1175, 1180, 1183, 1189, 1204, 1209, 1267, 1271, 1278, 1281, 1313, 1319, 1332, 1334, 1338, 1346, 1352, 1358, 1366, 1378, 1392, 1402, 1433, 1436, 1438 and so on in the nucleotide sequence of SEQ ID NO: 6 can be recited.

[0022] To be more specific, when the useful protein gene is a FLJ32130 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a FLJ32130 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 7 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 1 to 2379 in the nucleotide sequence described in Genbank Accession No. AC002310) can be recited. In the nucleotide sequence of SEQ ID NO: 7, ATG codon encoding methionine at amino terminal of FLJ32130 protein derived from human is represented in base No. 2136 to 2138, and a nucleotide sequence assumed to be the above exon 1 is represented in base No. 2136 to 2379. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 7, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 7 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1714, 1716, 1749, 1753, 1762, 1795, 1814, 1894, 1911, 1915, 1925, 1940, 1955, 1968 and so on in the nucleotide sequence of SEQ ID NO: 7 can be recited.

[0023] To be more specific, when the useful protein gene is a PPARG angiopoietin-related protein gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a PPARG angiopoietin-related protein gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 8 can be recited. In the nucleotide sequence of SEQ ID NO: 8, ATG codon encoding methionine at amino terminal of PPARG angiopoietin-related protein derived from human is represented in base No. 717 to 719, and a nucleotide sequence of the 5' side part of the above exon 1 is represented in base No. 1957 to 2661. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 8, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 8 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 35, 43, 51, 54, 75, 85, 107, 127, 129, 143, 184, 194, 223, 227, 236, 251, 258 and so on in the nucleotide sequence of SEQ ID NO: 8 can be recited.

[0024] To be more specific, when the useful protein gene is a Thrombomodulin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Thrombomodulin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 9 (corresponding to a nucleotide sequence represented by base No. 1 to 6096 in the nucleotide sequence described in Genbank Accession No. AF495471) can be recited. In the nucleotide sequence of SEQ ID NO: 9, ATG codon encoding methionine at amino terminal of Thrombomodulin protein derived from human is represented in base No. 2590 to 2592, and a nucleotide sequence of the above exon 1 is represented in base No. 2048 to 6096. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 9, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 9 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1539, 1551, 1571, 1579, 1581, 1585, 1595, 1598, 1601, 1621, 1632, 1638, 1645, 1648, 1665, 1667, 1680, 1698, 1710, 1724, 1726, 1756 and so on in the nucleotide sequence of SEQ ID NO: 9 can be recited.

[0025] To be more specific, when the useful protein gene is a p53-responsive gene 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a p53-responsive gene 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 10 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 113501 to 116000 in the nucleotide sequence described in Genbank Accession No. AC009471) can be recited. In the nucleotide sequence of SEQ ID NO: 10, a nucleotide

EP 2 272 975 B1

sequence of exon 1 of a p53-responsive gene 2 gene derived from human is represented in base No. 1558 to 1808. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 10 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1282, 1284, 1301, 1308, 1315, 1319, 1349, 1351, 1357, 1361, 1365, 1378, 1383 and so on in the nucleotide sequence of SEQ ID NO: 10 can be recited.

[0026] To be more specific, when the useful protein gene is a Fibrillin2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Fibrillin2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 11 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 118801 to 121000 in the nucleotide sequence described in Genbank Accession No. AC113387) can be recited. In the nucleotide sequence of SEQ ID NO: 11, a nucleotide sequence of exon 1 of a Fibrillin2 gene derived from human is represented in base No. 1091 to 1345. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 11 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 679, 687, 690, 699, 746, 773, 777, 783, 795, 799, 812, 823, 830, 834, 843 and so on in the nucleotide sequence of SEQ ID NO: 11 can be recited.

[0027] To be more specific, when the useful protein gene is a Neurofilament3 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Neurofilament3 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 12 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 28001 to 30000 in the nucleotide sequence described in Genbank Accession No. AF106564) can be recited. In the nucleotide sequence of SEQ ID NO: 12, a nucleotide sequence of exon 1 of a Neurofilament3 gene derived from human is represented in base No. 614 to 1694. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 12 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 428, 432, 443, 451, 471, 475, 482, 491, 499, 503, 506, 514, 519, 532, 541, 544, 546, 563, 566, 572, 580 and so on in the nucleotide sequence of SEQ ID NO: 12 can be recited.

[0028] To be more specific, when the useful protein gene is a disintegrin and metalloproteinase domain 23 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 13 (corresponding to a nucleotide sequence represented by base No. 21001 to 23300 in the nucleotide sequence described in Genbank Accession No. AC009225) can be recited. In the nucleotide sequence of SEQ ID NO: 13, a nucleotide sequence of exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human is represented in base No. 1194 to 1630. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 13 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 998, 1003, 1007, 1011, 1016, 1018, 1020, 1026, 1028, 1031, 1035, 1041, 1043, 1045, 1051, 1053, 1056, 1060, 1066, 1068, 1070, 1073, 1093, 1096, 1106, 1112, 1120, 1124, 1126 and so on in the nucleotide sequence of SEQ ID NO: 13 can be recited.

[0029] To be more specific, when the useful protein gene is a G protein-coupled receptor 7 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G protein-coupled receptor 7 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 14 (corresponding to a nucleotide sequence represented by base No. 75001 to 78000 in the nucleotide sequence described in Genbank Accession No. AC009800) can be recited. In the nucleotide sequence of SEQ ID NO: 14, a nucleotide sequence of exon 1 of a G protein-coupled receptor 7 gene derived from human is represented in base No. 1666 to 2652. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 14 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1480, 1482, 1485, 1496, 1513, 1526, 1542, 1560, 1564, 1568, 1570,

1580, 1590, 1603, 1613, 1620 and so on in the nucleotide sequence of SEQ ID NO: 14 can be recited.

[0030] To be more specific, when the useful protein gene is a G-protein coupled somatostatin and angiotensin-like peptide receptor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 15 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 57001 to 60000 in the nucleotide sequence described in Genbank Accession No. AC008971) can be recited. In the nucleotide sequence of SEQ ID NO: 15, a nucleotide sequence of exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human is represented in base No. 776 to 2632. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 15 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 470, 472, 490, 497, 504, 506, 509, 514, 522, 540, 543, 552, 566, 582, 597, 610, 612 and so on in the nucleotide sequence of SEQ ID NO: 15 can be recited.

[0031] To be more specific, when the useful protein gene is a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 16 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 78801 to 81000 in the nucleotide sequence described in Genbank Accession No. AC026802) can be recited. In the nucleotide sequence of SEQ ID NO: 16, a nucleotide sequence of exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human is represented in base No. 1479 to 1804. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 16 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1002, 1010, 1019, 1021, 1051, 1056, 1061, 1063, 1080, 1099, 1110, 1139, 1141, 1164, 1169, 1184 and so on in the nucleotide sequence of SEQ ID NO: 16 can be recited.

[0032] The term "methylated DNA antibody" means an antibody that binds to a methylated base in DNA as its antigen. Concretely, it may be a methylcytosine antibody, and an antibody having a property of recognizing and binding to cytosine methylated at position 5 in single-stranded DNA can be recited. Also a commercially available methylated DNA antibody may be applicable as far as it specifically recognizes and specifically binds to DNA in a methylated state according to the present invention.

[0033] A methylated DNA antibody can be prepared by a conventional immunological technique from a methylated base, methylated DNA or the like as an antigen. Concretely, a methylcytosine antibody can be obtained by selecting from antibodies prepared against an antigen such as 5-methylcytidine, 5-methylcytosine or DNA containing 5-methylcytosine according to specific binding to methylcytosine in DNA as an index.

[0034] As an antibody obtainable by immunizing an animal against an antigen, after immunizing with a purified antigen, an antibody of an IgG fraction (polyclonal antibody), and an antibody produced by a single clone (monoclonal antibody) can be used. In the present invention, since an antibody capable of specifically recognizing methylated DNA or methylcytosine is desired, it is preferable to use a monoclonal antibody.

[0035] As a method of preparing a monoclonal antibody, a procedure based on a cell fusion method can be recited. For example, in the cell fusion method, a hybridoma is prepared by allowing cell fusion between a pancreatic cell (B cell) derived from an immunized mouse and a myeloma cell, and an antibody produced by the hybridoma is selected, and thus a methylcytosine antibody (monoclonal antibody) is prepared. When a monoclonal antibody is prepared by a cell fusion method, it is not necessary to purify an antigen, and for example, a mixture of 5-methyl cytidine, 5-methylcytosine or DNA or the like containing 5-methylcytosine may be administered as an antigen to an animal used for immunization. As an administration method, 5-methyl cytidine, 5-methylcytosine or DNA or the like containing 5-methylcytosine is directly administered to a mouse for production of an antibody. When an antibody is difficult to be produced, an antigen bound to a support may be used for immunization.

[0036] Also, by thoroughly mixing an adjuvant solution (prepared, for example, by mixing liquid paraffin and Aracel A, and mixing killed tubercle bacilli as an adjuvant) and an antigen, and immunizing via liposome incorporating the same, immunity of an antigen can be improved. Also a method involving adding equivalent amounts of a solution containing an antigen and an adjuvant solution, fully emulsifying them, and subcutaneously or intraperitoneally injecting the resultant mixture to a mouse, and a method of adding killed Bordetella pertussis as an adjuvant after mixing well with alum water are known. A mouse may be boosted intraperitoneally or intravenously after an appropriate term from initial immunization.

When the amount of an antigen is small, a solution in which the antigen is suspended may be directly injected into a mouse spleen to effect immunization.

5 [0037] After exenterating a spleen and peeling an adipose tissue off after several days from the final immunization, a spleen cell suspension is prepared. The spleen cell is fused, for example, with an HGPRT-deficient myeloma cell to prepare a hybridoma. As a cell fusion agent, any means capable of efficiently fusing a spleen cell (B cell) and a myeloma cell is applicable, and for example, a method of using a hemagglutinating virus of Japan (HVJ), polyethyleneglycol (PEG) and the like are recited. Cell fusion may be conducted by a method using a high voltage pulse.

10 [0038] After the cell fusion operation, cells are cultured in an HAT medium, a clone of a hybridoma in which a spleen cell and a myeloma cell are fused is selected, and the cell is allowed to grow until screening becomes possible. In a method of detecting an antibody for selecting a hybridoma that produces an intended antibody, or a method of measuring a titer of an antibody, an antigen-antibody reaction system may be used. Concretely, as a method of measuring an antibody against a soluble antigen, a radioisotope immune assay (RIA), an enzyme-linked immunosorbent assay (ELISA) and the like can be recited.

15 [0039] Single-stranded DNA is able to bind with an anti methylation antibody as far as at least one position of a CpG existing therein is methylated. The term "methylated single-stranded DNA" in the present invention means single-stranded DNA in which at least one position of a CpG existing in single-stranded DNA is methylated, rather than meaning exclusively single-stranded DNA in which every CpG existing in single-stranded DNA is methylated.

20 [0040] The expression "an amount of amplified DNA obtained by (amplifying methylated DNA in a target DNA region to a detectable level" means an amount itself after amplification of methylated DNA in a target region comprised by genomic DNA contained in a biological specimen, namely, an amount determined in Third step of the present invention as described below. For example, when the biological specimen is 1 mL of serum, it means an amount of DNA amplified based on the methylated DNA contained in 1 mL of serum.

[0041] In First step, a DNA sample derived from genomic DNA contained in a biological specimen is subjected to a digestion treatment with a methylation-sensitive restriction enzyme.

25 [0042] The "methylation-sensitive restriction enzyme" in the present invention does not digest a recognition sequence containing methylated cytosine, but digests only a recognition sequence containing unmethylated cytosine. In other words, in the case of DNA wherein cytosine contained in a recognition sequence inherently recognizable by the methylation sensitive restriction enzyme is methylated, the DNA will not be cleaved even when the methylation sensitive restriction enzyme is caused to act on the DNA. On the other hand, in the case of DNA wherein cytosine contained in a recognition sequence inherently recognizable by the methylation sensitive restriction enzyme is not methylated, the DNA will be cleaved when the methylation sensitive restriction enzyme is caused to act on the DNA. Concrete examples of such methylation sensitive restriction enzymes include HpaII, BstUI, NarI, SacII, and HhaI which are restriction enzymes recognition cleavage site for which is present in the objective DNA region of the genomic DNA contained in a biological specimen. The aforementioned methylation sensitive restriction enzymes have already been revealed by Gruenbaum et al. (Nucleic Acid Research, 9, 2509-2515).

35 [0043] As a method of examining whether or not digestion by the methylation sensitive restriction enzyme occurs, concretely, for example, a method of conducting PCR using a pair of primers capable of amplifying DNA containing cytosine which is a target of analysis in a recognition sequence while using the DNA as a template, and examining whether or not the DNA is amplified (amplified product) can be recited. When the cytosine which is a target of analysis is methylated, an amplified product is obtained. On the other hand, when the cytosine which is a target of analysis is not methylated, an amplified product is not obtained. In this manner, by comparing the amounts of amplified DNA, it is possible to measure the methylated rate of the cytosine which is a target of analysis. In brief, when genomic DNA contained in the biological specimen is methylated, it is possible to distinguish whether or not cytosine in CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is methylated by utilizing the characteristic that the methylation sensitive restriction enzyme fails to cleave methylated DNA. In other words, when cytosine in at least one CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is not methylated, the DNA having such a recognition site will be cleaved by the methylation sensitive restriction enzyme when it is subjected to a digestion treatment with the methylation sensitive restriction enzyme. Further, when cytosine in every CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is methylated, the DNA having such a recognition site will not be cleaved by the methylation sensitive restriction enzyme. Therefore, by conducting PCR using a pair of primers capable of amplifying the objective DNA region as will be described later after executing the digestion treatment, an amplified product by PCR will not be obtained when cytosine in at least one CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is not methylated, and on the other hand, an amplified product by PCR will be obtained when cytosine in every CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is methylated.

55 [0044] Concretely, First step may be executed, for example, in the following manner when genomic DNA contained

in the biological specimen is genomic DNA from mammals. Genomic DNA from mammals is added with 3 μL of an optimum 10 x buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc_2 , 5 mM Dithiothreitol), 3 μL of 1 mg/mL BSA aqueous solution, each 1.5 μL of a methylation sensitive restriction enzyme such as HpaII or HhaI (10 U/ μL), and the resultant mixture is added with sterilized ultrapure water to make the liquid amount 30 μL , and incubated at 37°C for one to three hours.

[0045] The treatment with a methylation-sensitive restriction enzyme in First step includes addition of a masking oligonucleotide. In particular, the treatment comprises

[0046] First (A) step of mixing a single-stranded DNA (plus strand) containing the objective DNA region and a masking oligonucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of a recognition site for a methylation-sensitive restriction enzyme, thereby obtaining a partially single-stranded DNA in which the recognition site for the methylation-sensitive restriction enzyme forms double strand by complementary base-pairing with the masking oligonucleotide; followed by First (B) step of digesting the single-stranded DNA selected in First (A) step with the methylation-sensitive restriction enzyme. In particular, therefore, a masking oligonucleotide is added to a solution for the treatment with a methylation-sensitive restriction enzyme.

[0047] By undergoing First (A) and First (B) steps, any DNA sample derived from a genomic DNA contained in a biological specimen may be digested with a methylation-sensitive restriction enzyme with double-stranded DNA exclusively as a substrate, even if the DNA sample is single-stranded DNA.

[0048] The term "masking oligonucleotide" means oligonucleotide having a nucleotide sequence complementary to the nucleotide sequence of the recognition site of the methylation sensitive restriction enzyme, and is oligonucleotide that forms double strand by complementary base-pairing at least one site (even every site is possible) of several recognition sites of the methylation sensitive restriction enzyme contained in the objective DNA region in the single-stranded DNA (that is, the site is made into double-stranded state), thereby enabling the methylation sensitive restriction enzyme that uses only double-stranded DNA as a substrate to digest the site, and improving digestion efficiency at the site for the methylation sensitive restriction enzyme capable of digesting single-stranded DNA (methylation sensitive restriction enzyme capable of digesting single-stranded DNA also digests double-stranded DNA, and digestion efficiency thereof is higher with respect to double-stranded DNA than with respect to single-stranded DNA), and means oligonucleotide not inhibiting formation of double strand between single-stranded DNA containing the objective DNA region and single-stranded immobilized oligonucleotide. Further, when a sample is a single-stranded DNA, the masking oligonucleotide should be oligonucleotide that is unavailable in a reaction for extending an extension primer by using a later-described reverse primer (plus strand) as the extension primer and the masking oligonucleotide (minus strand) as a template. As a nucleotide length, 8 to 200 bases long is preferred.

[0049] The masking oligonucleotide to be mixed with a DNA sample derived from genomic DNA may be one kind or plural kinds. When plural kinds are used, many of recognition sites of the methylation sensitive restriction enzyme in the single-stranded DNA containing the objective DNA region become double-strand state, and "DNA remaining undigested" as will be described later by the methylation sensitive restriction enzyme can be minimized. For example, it is particularly useful to use the masking oligonucleotide designed in accordance with a site intended not to be digested when it is methylated and intended to be digested when it is not methylated among several recognition sequences of the methylation sensitive restriction enzyme contained in the objective DNA region (for example, the site that is methylated at 100% in a diseased patient specimen, but is not methylated at 100% in a healthy specimen).

[0050] As a concern in a digestion treatment in First step, a fear that a recognition sequence containing non-methylated cytosine cannot be completely digested (so called "DNA remaining undigested") can be recited. When such a fear is problematic, since the "DNA remaining undigested" can be minimized if recognition sites of the methylation sensitive restriction enzyme abundantly exist, it is considered that as the objective DNA region, the one having one or more recognition sites of the methylation sensitive restriction enzyme is preferred and the more the better.

[0051] One preferable embodiment is that "a DNA sample derived from a genomic DNA contained in a biological specimen" is a DNA sample digested in advance with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region possessed by the genomic DNA. Here, when a digested substance of a genomic DNA contained in a biological specimen is selected with the use of present immobilized oligonucleotide, shorter template DNA is more likely to be selected, and when the objective region is amplified by PCR, shorter template DNA is more preferred. Therefore, a digestion treatment may be executed while using a restriction enzyme whose recognition cleavage site excludes the objective DNA region directly on the DNA sample derived from a genomic DNA contained in a biological specimen. As a method of digesting with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region, a commonly used restriction enzyme treatment method may be used. These embodiments are preferred because the methylation amount can be determined accurately by digesting the biological specimen itself in advance with a restriction enzyme as described above. Such a method is useful for avoiding the "DNA remaining undigested" as described above.

[0052] As a method of digesting a sample derived from a genomic DNA contained in a biological specimen with the methylation sensitive restriction enzyme, when the biological specimen is a genomic DNA itself, the method similar to

that described above is preferred, and when the biological specimen is a tissue lysate, a cell lysate or the like, a digestion treatment may be executed using a large excess of methylation sensitive restriction enzyme, for example, a methylation sensitive restriction enzyme in an amount of 500 times (10 U) or more with respect to 25 ng of the DNA amount, according to a similar method as described above.

5 **[0053]** Basically, genomic DNA exists as double-stranded DNA. Therefore, in the present operation, not only a methylation sensitive restriction enzyme (for example, HhaI) capable of digesting single-stranded DNA, but also a methylation sensitive restriction enzyme capable of digesting double-stranded DNA (for example, HpaII, BstUI, NarI, SacII, HhaI and the like) may be used.

10 **[0054]** In Second step of the present measuring method, methylated single-stranded DNA is obtained from the DNA sample that has been subjected to the digestion treatment and obtained in First step, and the methylated single-stranded DNA is bound to an immobilized methylated DNA antibody, thereby selecting the single-stranded DNA. Second step comprises a Second (A) step of separating into methylated single-stranded DNA the methylated double-stranded DNA contained in the DNA sample that has been subjected to the digestion treatment and obtained in First step; and Second (B) step of binding the methylated single-stranded DNA obtained in Second (A) step to an immobilized methylated DNA antibody.

15 **[0055]** In Second (A) step of the present measuring method, in "separating into methylated single-stranded DNA the methylated double-stranded DNA contained in the DNA sample that has been subjected to the digestion treatment and obtained in First step", a commonly used operation for making double-stranded DNA into single-stranded DNA may be conducted. Concretely, a DNA sample derived from genomic DNA contained in a biological specimen may be dissolved in an appropriate amount of ultrapure water, heated at 95°C for 10 minutes, and rapidly cooled on ice.

20 **[0056]** In Second (B) step, the methylated single-stranded DNA obtained in Second (A) step is bound to an immobilized methylated DNA antibody, thereby selecting the single-stranded DNA. The immobilized methylated DNA antibody is used for selecting methylated single-stranded DNA from a DNA sample derived from genomic DNA contained in a biological specimen. The immobilized methylated DNA antibody may be one immobilizable to a support, and the expression "one immobilizable to a support" means that a immobilized methylated DNA antibody can be immobilized to a support directly or indirectly. For achieving such immobilization, a immobilized methylated DNA antibody may be immobilized to a support according to a commonly used genetic engineering operation method or a commercially available kit, apparatus or the like (binding to a solid phase). Concretely, a method of immobilizing a biotinylated immobilized methylated DNA antibody obtained by biotinylating an immobilized methylated DNA antibody to a support coated with streptavidin (for example, a PCR tube coated with streptavidin, magnetic beads coated with streptavidin and so on) can be recited.

25 **[0057]** Also there is a method of letting a molecule having an active functional group such as an amino group, a thiol group, or an aldehyde group covalently bind to an immobilized methylated DNA antibody, and letting the resultant bound body covalently bind to a support made of glass, a polysaccharide derivative, silica gel, the synthetic resin or thermostable plastic whose surface is activated with a silane coupling agent or the like. Covalent bonding may be achieved, for example, using a spacer formed by serially connecting five triglycerides, a cross linker or the like.

30 **[0058]** An immobilized methylated DNA antibody may be directly immobilized to a support, or an antibody against an immobilized methylated DNA antibody (secondary antibody) may be immobilized to a support, and a methylated antibody may be bound to the secondary antibody to achieve immobilization to a support.

35 **[0059]** It suffices that the present immobilized immobilized methylated DNA antibody is immobilized to a support when single-stranded DNA (plus strand) containing the objective DNA region is selected, and (1) immobilization may be achieved by binding between the present immobilized immobilized methylated DNA antibody and a support before binding between the single-stranded DNA (plus strand) and the present immobilized immobilized methylated DNA antibody, or (2) immobilization may be achieved by binding between the present immobilized methylated DNA antibody and a support after binding between the single-stranded DNA (plus strand) and the present immobilized immobilized methylated DNA antibody.

40 **[0060]** In Second (B) step, when "the single-stranded DNA is selected by binding between methylated single-stranded DNA and an immobilized immobilized methylated DNA antibody," it may be concretely executed in the following manner, for example, using a "biotin-labeled biotinylated methylated cytosine antibody" as an immobilized immobilized methylated DNA antibody.

45 (a) An avidin-coated PCR tube is added with an appropriate amount (for example, 0.1 $\mu\text{g}/50 \mu\text{L}$) of a biotinylated, methylated cytosine antibody, left still at room temperature for about an hour, to promote immobilization between the biotinylated methylated cytosine antibody and streptavidin. Then the remaining solution is removed and washing is performed. A washing buffer [for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)] is added in a proportion of 100 $\mu\text{L}/\text{tube}$, and the solution is removed. This washing operation is repeated several times, to leave the biotinylated methylated cytosine antibody immobilized to a support inside the PCR tube.

(b) Double-stranded DNA derived from genomic DNA contained in a biological specimen is mixed with a buffer (for example, 33 mM Tris-Acetate pH 7.9, 66 mM KOAc, 10 mM MgOAc₂, 0.5 mM Dithiothreitol) and heated at 95°C for several minutes. Then the reaction is rapidly cooled to about 0 to 4°C, and kept for several minutes at this temperature to cause formation of single-stranded DNA. Then the reaction is returned to room temperature.

(c) The formed single-stranded DNA is added to an avidin-coated PCR tube to which a biotinylated methylated cytosine antibody is immobilized, and then left still at room temperature for about an hour, to promote binding between the biotinylated methylated cytosine antibody and methylated single-stranded DNA among the single-stranded DNA (formation of a bound body)(in this stage, at least single-stranded DNA containing an unmethylated DNA region does not form a bound body). Thereafter, the remaining solution is removed and washing is performed. A washing buffer [for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] is added in a proportion of 100 μL/tube, and the solution is removed. This washing operation is repeated several times, to leave the bound body inside the PCR tube (selection of a bound body).

[0061] The buffer used in (b) is not limited to the above buffer and may be any buffer that is suited for separating double-stranded DNA derived from genomic DNA from a biological sample into single-stranded DNA.

[0062] The washing operation in (a) and (c) is important for removing an immobilized methylated DNA antibody suspended in the solution, unmethylated single-stranded DNA that does not bind with a immobilized methylated DNA antibody and hence is suspended in the solution, and DNA suspended in a solution digested by a restriction enzyme as will be described later, from the reaction solution. The washing buffer is not limited to the foregoing washing buffer, and any buffer suited for removing the free immobilized methylated DNA antibody, single-stranded DNA and so on suspended in the solution and the like is applicable, and a DELFIA buffer (available from Perkin Elmer, Tris-HCl pH 7.8 with Tween 80), a TE buffer and the like may be used.

[0063] In Second (A) step, as a preferred embodiment in separating methylated single-stranded DNA, addition of a counter oligonucleotide and the like can be recited. A counter oligonucleotide means a short oligonucleotide comprising a part of the same nucleotide sequence as that of the objective DNA region. It may be designed to have a length of usually 10 to 100 bases, and more preferably 20 to 50 bases. Here, a counter oligonucleotide is not designed on the nucleotide sequence where a forward primer or a reverse primer complementarily binds with the target DNA region. A counter oligonucleotide is added in excess relative to genomic DNA, and is added so as to prevent a complementary strand of a target DNA region (minus strand) and a single strand of a target DNA region (plus strand) from re-binding by complementation when binding with an immobilized methylated DNA antibody is caused after making a target DNA region into a single strand (plus strand). This is because in measuring a methylation frequency of DNA or an index value having correlation therewith while a methylated DNA antibody is bound to the target DNA region, the target region is more likely to bind with the methylated DNA antibody when it is a single strand. Preferably, a counter oligonucleotide is added in an amount of at least 10 times, usually 100 times or more relative to the target DNA region.

[0064] "Adding a counter oligonucleotide in separating methylated single-stranded DNA" may be concretely achieved by mixing a DNA sample derived from genomic DNA contained in a biological specimen with a counter oligonucleotide to form a double strand between the complementary strand of the target DNA region and the counter oligonucleotide so as to select methylated single-stranded DNA from a DNA sample derived from genomic DNA contained in a biological specimen. For example, the DNA sample and the counter oligonucleotide are added to 5 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μL of a 100 mM MgCl₂ solution, and 5 μL of a 1 mg/mL of BSA solution, and the resultant mixture is added with sterile ultrapure water to a liquid volume of 50 μL, and mixed, heated at 95°C for 10 minutes, rapidly cooled to 70°C, kept at this temperature for 10 minutes, then cooled to 50°C, kept at this temperature for 10 minutes, and then kept at 37°C for 10 minutes and returned to room temperature.

[0065] Disclosed herein is a third step comprising, as a pre step of each of the following regular steps:

a step (First pre step) of separating the single-stranded DNA selected in Second step from the immobilized immobilized methylated DNA antibody to provide DNA in a single-stranded state (plus strand);

a step (Second pre step) of extensionally-forming a double-stranded DNA from a single-stranded DNA (plus strand) containing the objective DNA region by a single extension of an extension primer, using the genomic DNA (plus strand) provided in a single-stranded state in First pre step and the extension primer, wherein the extension primer (forward primer) comprises the nucleotide sequence (minus strand) complementary to a partial nucleotide sequence (plus strand) of the nucleotide sequence of the DNA in a single-stranded state (plus strand), the partial nucleotide sequence (plus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (plus strand) of the objective DNA region; and

a step (Third pre step) of temporarily separating the double-stranded DNA extensionally formed in Second pre step into a single-stranded DNA (plus strand) containing the objective DNA region and a single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region;

and as regular steps:

(a) Step A (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA containing the objective DNA region, by a single extension of the extension primer, using as a template the generated single-stranded DNA (plus strand) containing the objective DNA region, and the forward primer as the extension primer; and
 (b) Step B (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA containing the objective DNA region, by a single extension of an extension primer, using as a template the generated single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region, and using as the extension primer an extension primer (reverse primer) comprising the nucleotide sequence (plus strand) complementary to a partial nucleotide sequence (minus strand) of the nucleotide sequence of the single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region, the partial nucleotide sequence (minus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (minus strand) complementary to the nucleotide sequence (plus strand) of the objective DNA region; and wherein Third step further comprises amplifying the methylated DNA in the objective DNA region to a detectable level by repeating each regular step of Third step after temporarily separating the extensionally formed double-stranded DNA obtained in each of the regular steps into a amplified DNA.

[0066] In Third step discussed above, first, as First pre step among the respective pre steps of the following regular steps, single-stranded DNA selected in Second step is temporarily separated from the immobilized methylated DNA antibody into DNA in a single-stranded state. Concretely, for example, by adding an annealing buffer to single-stranded DNA selected in Second step, a mixture is obtained. Then the resultant mixture is heated at 95°C for several minutes, to obtain DNA in a single-stranded state (plus strand). Thereafter, in Second pre step, concretely, for example, DNA in a single-stranded state (plus strand) obtained in First pre step and a forward primer are mixed in a solution that is prepared by adding 17.85 μ L of sterile ultrapure water, 3 μ L of an optimum buffer (for example, 100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂), 3 μ L of 2 mM dNTP, and 6 μ L of 5 N betaine, and adding the resultant mixture with 0.15 μ L of AmpliTaq (a kind of DNA polymerase: 5 U/ μ L) to a liquid volume of 30 μ L, and incubated at 37°C for about two hours, to extensionally form double-stranded DNA from the single-stranded DNA (plus strand) containing an objective DNA region. In Third pre C step, concretely, for example, the double-stranded DNA extensionally formed in Second pre step is added with an annealing buffer to obtain a mixture, and the DNA is temporarily separated into single-stranded DNA containing the target DNA region by heating the mixture at 95°C for several minutes.

[0067] Thereafter, the following regular steps are conducted.

(i) The reaction is rapidly cooled to a temperature lower than T_m of the forward primer by about 0 to 20°C, and kept at this temperature for several minutes for annealing the forward primer to the generated single-stranded DNA (plus strand) containing the target DNA region.

(ii) Thereafter, the reaction is returned to room temperature.

(iii) Double-stranded DNA is extensionally formed from single-stranded DNA comprising the nucleotide sequence complementary to the objective DNA region by one extension of an extension primer by using the DNA in a single-stranded state annealed in the above (i) as a template, and the forward primer as an extension primer (namely, Step A). Concretely, it may be executed, for example, according to the later-described explanation, or the operation method in an extension reaction in Second pre step of the present invention as described above.

(iv) Single-stranded DNA is made into extensionally formed double-stranded DNA by one extension of an extension primer by using the generated single-stranded DNA (minus strand) comprising the nucleotide sequence complementary to the target DNA region as a template, and an extension primer (reverse primer) comprising a nucleotide sequence (plus strand) which is complementary to a partial nucleotide sequence (minus strand) of the nucleotide sequence comprised by the single-stranded DNA (minus strand) containing the target DNA region, the partial nucleotide sequence (minus strand) located on further 3'-end side than 3'-end of the nucleotide sequence (minus strand) complementary to the nucleotide sequence (plus strand) of the target DNA region as the extension primer (namely, Step B). Concretely, it may be executed, for example, according to the operation method in an extension reaction in Second pre step similarly to Step A of the above (iii).

(v) By repeating the regular steps of Third step after temporarily separating the extensionally formed double-stranded DNA obtained in each of the regular steps into a single-stranded state (for example, Step A and Step B), the methylated DNA in the objective DNA region is amplified to a detectable level and a content of the amplified DNA is quantified.

[0068] In Third step, discussed above, concretely the reaction starting from First pre step and up to regular steps may be executed as a single PCR reaction. Also, from First pre step step to Third pre step, each reaction may be independently executed, and only regular steps may be executed as a PCR reaction.

[0069] As a method of amplifying an objective DNA region (namely, an objective region) contained in the selected single-stranded DNA, PCR is used. Using a primer preliminarily labeled with fluorescence or the like and utilizing the label as an index in amplifying the target region make it possible to evaluate presence or absence of an amplification product without executing a burdensome operation such as electrophoresis. As a PCR reaction solution, for example, a reaction solution obtained by mixing DNA obtained in Second step of the present measuring method with 0.15 μL of a 50 μM primer solution, 2.5 μL of 2 mM dNTP, 2.5 μL of a $10 \times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl 20 mM MgCl_2 , 0.01% Gelatin), and 0.2 μL of AmpliTaq Gold (one kind of thermostable DNA polymerase: 5 U/ μL), and adding sterilized ultrapure water to make the liquid volume 25 μL can be recited.

[0070] Since an objective DNA region (namely, an objective region) often has a GC rich nucleotide sequence, the reaction may be occasionally executed with addition of an appropriate amount of betaine, DMSO or the like. In one exemplary reaction condition, the reaction solution as described above is kept at 95°C for 10 minutes, and then a cycle including incubation of 30 seconds at 95°C, 30 seconds at 55 to 65°C, and 30 seconds at 72°C is repeated 30 to 40 times. After conducting such PCR, the obtained amplification product is detected. For example, when a preliminarily labeled primer is used, an amplification amount by a PCR reaction can be evaluated by measuring an amount of a fluorescent label after executing washing and purification operations similar to those as described above. When PCR is conducted using a normal primer that is not labeled, a probe or the like that is labeled with a gold colloid particle, fluorescence or the like is caused to anneal, and detection may be achieved by measuring an amount of the probe bound to the target region. Also, for determining an amount of an amplification product more accurately, for example, a real time PCR method may be used. Real time PCR is a method in which PCR is monitored in real time, and the obtained monitor result is analyzed kinetically, and is known as a high-accuracy quantitative PCR method capable of detecting a very small difference of as small as twice in a gene amount. As such a real time PCR method, for example, a method using a probe such as a template-dependent nucleic acid polymerase probe, a method using an intercalator such as SYBR-Green and the like can be recited. As an apparatus and a kit for the real time PCR method, those commercially available may be used. As described above, detection may be executed by any method conventionally well-known without any particular limitation. These methods make it possible to conduct the operations up to detection without requiring change of the reaction container.

[0071] The present invention may be used in the following situations.

[0072] It is known that DNA methylation abnormality occurs in various diseases (for example, cancer), and it is believed that the degree of various diseases can be measured by detecting this DNA methylation abnormality.

[0073] For example, when there is a DNA region where methylation occurs at 100% in genomic DNA contained in a diseased biological specimen, and the present invention is executed for the DNA region, the amount of methylated DNA will increase. For example, when there is a DNA region where methylation does not occur at 100% in genomic DNA contained in a diseased biological specimen, and the present measuring method is executed for the DNA region, the amount of methylated DNA will be approximately 0. For example, when there is a DNA region which is in hypomethylation in genomic DNA contained in a specimen derived from a healthy subject, and in hypermethylation in genomic DNA contained in a specimen derived from a disease subject, and the present measuring method is executed for the DNA region, the amount of methylated DNA would be approximately 0 for the healthy subject, and a significantly higher value than that of the healthy subject will be exhibited by the disease patient, so that the "degree of disease" can be determined based on this difference in value. The "degree of disease" used herein has the same meaning commonly used in this field of art, and concretely means, for example, malignancy when the biological specimen is a cell, and means, for example, abundance of disease cells in the tissue when the biological specimen is a tissue. Further, when the biological specimen is plasma or serum, it means the probability that the individual has the disease. Therefore, the present measuring method makes it possible to diagnose various diseases by examining methylation abnormality.

[0074] Restriction enzymes, primers or probes that can be used in various methods for measuring a methylated DNA amount in a target region in the present measuring method are useful as reagents of a detection kit. The present invention also provides a detection kit containing these restriction enzymes, primers or probes as reagents, and a detection chip in which these primers, probes and so on are immobilized on a support, and a scope of the present measuring method or the present methylation rate measuring method of course embraces use in the form of a detection kit or a detection chip as described above utilizing the substantial principle of the method.

Examples

[0075] In the following, the present invention will be explained in detail by way of examples, however, the present invention will not be limited to these examples.

Example 1

[0076] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled

EP 2 272 975 B1

with biotin using a commercially available biotinylating kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.1 µg/100 µL solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)].

5 **[0077]** To each PCR tube coated with streptavidin (a total of 9 tubes), 50 µL of the synthetically obtained biotin-labeled methylcytosine antibody solution was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 µL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized

10 methylated DNA antibody used in the present measuring method).
[0078] A partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which a recognition site of HpaII comprising the nucleotide sequence of SEQ ID NO: 17 is methylated; a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of a recognition site of HpaII having the nucleotide sequence of SEQ ID NO: 18 is not methylated; and an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM having the nucleotide

15 sequence of SEQ ID NO: 19 were synthesized, and a 0.001 pmol/10 µL solution in a TE buffer was prepared for each oligonucleotide.
<Partially methylated oligonucleotide in which recognition sequence of HpaII is methylated>

20 **[0079]** N denotes methylated cytosine.
GPR7-2079-2176/98mer-M(7):

5' -

25 **GTTGGCCACTGCGGAGTCGNGCNGGGTGGCNGGCCGCACCTACAGNGCCGNGNGNGCGGTGA**
GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 17)

30 <Partially methylated oligonucleotide in which recognition sequence of HpaII is not methylated>

[0080] N denotes methylated cytosine.
GPR7-2079-2176/98mer-HM(5):

35 5' -

GTTGGCCACTGCGGAGTCGCGCCGGGTGGCNGGCCGCACCTACAGNGCCGNGNGNGCGGTGA
40 **GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 18)**

<Unmethylated oligonucleotide>

45 **[0081]** GPR7-2079-2176/98mer-UM:

5' -

GTTGGCCACTGCGGAGTCGCGCCGGGTGGCCGGCCGCACCTACAGCGCCGCGCGCGGTGA
50 **GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 19)**

[0082] Each of the obtained solutions (each solution was prepared in triplicate) was subjected to the following A treatment, B treatment or C treatment (each prepared singly).

55 **[0083]** A treatment group (no treatment group): The sample prepared above was added with 5 µL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), and 5 µL of BSA (Bovine serum albumin 1 mg/mL), and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 µL.

[0084] B treatment group (HpaII treatment group): The sample prepared above was added with 5 µL of a buffer (330

EP 2 272 975 B1

mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μL of BSA (Bovine serum albumin 1 mg/mL), and 10 U of HpaII, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μL.

[0085] C treatment group (addition of masking oligonucleotide + HpaII treatment group): The sample prepared above was added with 5 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μL of BSA (Bovine serum albumin 1 mg/mL), 10 U of HpaII, and 5 pmol of the oligonucleotide MA comprising the nucleotide sequence of SEQ ID NO: 20 as masking oligonucleotide, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μL.

<Masking oligonucleotide>

[0086]

MA: 5'-GCCACCCGGCGCGA-3' (SEQ ID NO: 20)

[0087] Each reaction mixture was incubated overnight at 37°C (these correspond to First step of the present invention).

[0088] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μL of a reaction solution of an oligonucleotide prepared as described above, and left still for an hour at room temperature. Then the solution was removed by pipetting, and 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Second step of the present invention).

[0089] Next, the above PCR tube was subjected to PCR using each solutions of a primer comprising the nucleotide sequences of SEQ ID NO: 21 and a primer comprising the nucleotide sequences of SEQ ID NO: 22 (PF1 and PR1), and the following reaction condition, to amplify methylated DNA in a target DNA region (GPR7-2079-2176, SEQ ID NO: 23, methylated cytosine is also denoted by C).

<Primers>

[0090]

PF1: 5'-GTTGGCCACTGCGGAGTCG-3' (SEQ ID NO: 21)

PR1: 5'-GCACGACGAGTGTGACGATC-3' (SEQ ID NO: 22)

<Target DNA region>

[0091]

GPR7-2079-2176: 5' -

GTTGGCCACTGCGGAGTCGCGCCGGGTGGCCGGCCGCACCTACAGCGCCGCGCGCGGGTGA

GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 23)

[0092] A reaction solution of PCR was prepared by mixing each 5 μL of a solution of primer comprising the nucleotide sequence of SEQ ID NO: 21 and a solution of primer comprising the nucleotide sequence of SEQ ID NO: 22 prepared to 3 μM, each 5 μL of 2 mM dNTPs, 5 μL of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), 0.25 μL of 5 U/μL thermostable DNA polymerase (AmpliTaq Gold), and 10 μL of a 5 N betaine aqueous solution to DNA which is a template, and adding sterile ultrapure water to a liquid volume of 50 μL. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 25 cycles of incubation each including 30 seconds at 95°C-, 30 seconds at 59°C, and 45 seconds at 72°C.

[0093] After conducting PCR, the amplification of DNA was checked by 2% agarose gel electrophoresis (these correspond to Third step of the present invention). The result is shown in Fig. 1.

[0094] In the case of A treatment group (no treatment group), in the partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, and the partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, amplification of DNA was observed, and an amplification product thereof (target DNA region: GPR7-2079-2176) was obtained. In the unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, amplification of DNA was not observed,

and an amplification product thereof was not obtained. Also in the case of B treatment group (HpaII treatment group), the result was similar to that in A treatment group. In the case of C treatment group (addition of masking oligonucleotide + HpaII treatment group), in the partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, amplification of DNA was observed, and an amplification product thereof (target DNA region: GPR7-2079-2176) was obtained. Contrarily, in the cases of the partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, and in the unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, amplification of DNA was not observed, and an amplification product thereof was not obtained.

[0095] From the above, it was demonstrated that single-stranded DNA containing a methylated target DNA region can be selected by an immobilized methylated cytosine antibody, and a target DNA region in which methylation sensitive restriction enzyme recognition site is unmethylated and protected by a masking oligonucleotide can be digested by a treatment with a methylation sensitive restriction enzyme after addition and mixing of a masking oligonucleotide, and only methylated DNA can be amplified to a detectable level and an amount of amplified DNA can be quantified while unmethylated DNA in the target DNA region is not amplified.

Example 2

[0096] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylation kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 μg/μL solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)].

[0097] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μL of the synthetically obtained biotin-labeled methylcytosine antibody solution was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0098] For genomic DNA derived from human blood purchased from Clontech, a DNA fragment (X, SEQ ID NO: 26, a region corresponding to the base numbers 25687390 to 25687775 shown in Genbank Accession No. NT_029419 and so on) to be used as a test sample was amplified by conducting PCR using an oligonucleotide primer of SEQ ID NO: 24 and an oligonucleotide primer of SEQ ID NO: 25 (PF2 and PR2) and the following reaction condition.

<Oligonucleotide primers designed for PCR>

[0099]

PF2: 5'-CTCAGCACCCAGGCGGCC-3' (SEQ ID NO: 24)
PCR2: 5'-CTGGCCAAACTGGAGATCGC-3' (SEQ ID NO: 25)

<DNA fragment>

[0100]

X: 5' -

CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCGCGGGCTGTTGCAGAGTCTT
 5 GAGCGGGTGGCACACCGCGATGTAGCGGTGGCTGTCATGACTACCAGCATGTAGGCCGACG
 CAAACATGCCGAACACCTGCAGGTGCTTCACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG
 10 CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTGGC
 CAGGCTGAGGTGTGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGCGTCCGGTGCAGAG
 15 CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC
 TCCAGTTTGGCCAG-3' (SEQ ID NO: 26)

[0101] As a reaction solution of PCR, 5 ng of genomic DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a 10 \times buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 40 cycles of incubation each including 30 seconds at 95°C, 30 seconds at 61°C, and 45 seconds at 72°C.

[0102] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis, and a DNA fragment X was purified with Wizard SV Gel/PCR Kit (PROMEGA).

[0103] For a part of the obtained DNA fragment solution, a reaction solution was prepared by mixing 1 μ L of SssI methylase (available from NEB), 10 μ L of a 10 \times NEBuffer 2 (available from NEB), and 1 μ L of S-adenosyl methionine (3.2 mM, available from NEB), and adding sterile ultrapure water to a liquid volume of 100 μ L. The reaction solution was incubated at 37°C for 15 to 30 minutes, and further added with 1 μ L of S-adenosyl methionine (3.2 mM, available from NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified with Wizard SV Gel/PCR Kit (PROMEGA). These operations were repeated another 5 times, to obtain a methylated DNA fragment (MX, SEQ ID NO: 27).

<DNA fragment> (N denotes 5-methylcytosine.)

[0104]

MX: 5' -

CTCAGCACCCAGGNGGCNNGATCATGAGGNGNGAGNGGNGNGNGGGCTGTTGCAGAGTCTT
 40 GAGNGGGTGGCACACNNGATGTAGNGGTNGGCTGTCATGACTACCAGCATGTAGGCCNGANG
 CAAACATGCNGAACACCTGCAGGTGCTTCACCANGNGGCACAGCCAGTNGGGGCNNGGAAG
 45 NGGTAGGTGATGTCCCAGCACATTTGNGGCAGCACCTGGAAGAATGCCANGGCCAGGTNGGC
 CAGGCTGAGGTGTNGGATGAAGAGGTGCATGNGGGANGTCTTGNGNGGNGTCNNGTGCAGAG
 50 CCAGCAGTANGCTGCTGTTGCCAGCANGGCCACNNGAAAGTCACNGCCAGCANGGNGATC
 TCCAGTTTGGCCAG-3' (SEQ ID NO: 27)

[0105] For each obtained DNA fragment X, the following solutions were prepared.

Solution A: 100 pg/5 μ L solution in TE

Solution B: 10 pg/5 μ L solution in TE

Solution C: 1 pg/5 μ L solution in TE

Solution D: TE solution (negative control solution)

EP 2 272 975 B1

[0106] For each obtained DNA fragment MX, the following solutions were prepared.

Solution MA: 100 pg/5 μ L solution in TE
Solution MB: 10 pg/5 μ L solution in TE
Solution MC: 1 pg/5 μ L solution in TE
Solution MD: TE solution (negative control solution)

[0107] For each of the solutions of the DNA fragment X and the solutions of the methylated DNA fragment MX, the following treatment was executed.

[0108] Five (5) μ L of the DNA fragment solution prepared above was added with 2 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μ L of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme-HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μ L. Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

[0109] Counter oligonucleotides C1 to C12 comprising the nucleotide sequences of SEQ ID NO: 29 to SEQ ID NO: 40 capable of complementarily base-pairing with a minus strand of the target DNA region X' comprising the nucleotide sequence of SEQ ID NO: 28 were synthesized, and each 0.01 μ M solutions in TE buffer were prepared.

<Target DNA region>

[0110]

X' : 5' -

CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCGCGGGCTGTTGCAGAGTCTT
GAGCGGGTGGCACACCGCGATGTAGCGGTGGCTGTCATGACTACCAGCATGTAGGCCGACG
CAAACATGCCGAACACCTGCAGGTGCTTACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG
CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTCGGC
CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGGCTCCGGTGCAGAG
CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC
TCCAGTTTGGCCAG-3' (SEQ ID NO: 28)

<Counter oligonucleotides>

[0111]

C1:5' - GCCACCGCGAAAGTCACCGCCAGCACGGCG -3' (SEQ ID NO: 29)
C2:5' - GCCAGCAGTACGCTGCTGTTGCCAGCACG -3' (SEQ ID NO: 30)
C3:5' - CGGGACGTCTTGCGCGGGCGTCCGGTGCAGA -3' (SEQ ID NO: 31)
C4:5' - AGGCTGAGGTGTCGGATGAAGAGGTGCATG -3' (SEQ ID NO: 32)
C5:5' - ACCTGGAAGAATGCCACGGCCAGGTCGGCC -3' (SEQ ID NO: 33)
C6:5' - TAGGTGATGTCCCAGCACATTTGCGGCAGC -3' (SEQ ID NO: 34)
C7:5' - CGGCACAGCCAGTCGGGGCCGCGGAAGCGG -3' (SEQ ID NO: 35)
C8:5' - ATGCCGAACACCTGCAGGTGCTTACCACG -3' (SEQ ID NO: 36)
C9:5' - ATGACTACCAGCATGTAGGCCGACGCAAAC -3' (SEQ ID NO: 37)
C10:5' - TGGCACACCGCGATGTAGCGGTGGCTGTC -3' (SEQ ID NO: 38)
C11:5' - CGCGCGGGCTGTTGCAGAGTCTTGAGCGGG -3' (SEQ ID NO: 39)
C12:5' - CAGGCGGGCCGCGATCATGAGGCGCGAGCGG -3' (SEQ ID NO: 40)

[0112] To the above reaction solution, 10 μ L of a counter oligonucleotide solution prepared as described above, 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of a 100 mM MgCl₂ solution, and 5 μ L of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile

EP 2 272 975 B1

ultrapure water to a liquid volume of 50 μL , and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

[0113] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μL of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

[0114] Then by subjecting the above PCR tube to PCR using respective solutions of oligonucleotide primers PF2 and PR2 comprising the nucleotide sequences of SEQ ID NO: 24 and SEQ ID NO: 25, and the following reaction condition, methylated DNA in a target DNA region X' comprising the nucleotide sequence of SEQ ID NO: 28 was amplified.

<Oligonucleotide primers designed for PCR>

[0115]

PF2: 5'-CTCAGCACCCAGGCGGCC-3' (SEQ ID NO: 24)

PR2: 5'-CTGCCAAACTGGAGATCGC-3' (SEQ ID NO: 25)

<Target DNA region>

[0116]

X' : 5' -

CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCGCGGGCTGTTGCAGAGTCTT

GAGCGGGTGGCACACCGCGATGTAGCGGTCTGGCTGTCATGACTACCAGCATGTAGGCCGACG

CAAACATGCCGAACACCTGCAGGTGCTTACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG

CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTCGGC

CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGCGTCCGGTGCAGAG

CCAGCAGTACGCTGCTGTTGCCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC

TCCAGTTTGCCAG-3' (SEQ ID NO: 28)

[0117] As a reaction solution of PCR, DNA which is a template, mixed with each 3 μL of oligonucleotide primer solutions prepared to 5 μM , each 5 μL of 2 mM dNTPs, 5 μL of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl 15 mM MgCl_2 , 0.01% Gelatin), and 0.25 μL of 5 U/ μL thermostable DNA polymerase (AmpliAq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μL was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 25 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 61°C, and 30 seconds at 72°C.

[0118] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis (these correspond to Fourth step of the present measuring method).

[0119] The result is shown in Fig. 2. In Solutions MA, MB and MC of the methylated DNA fragment MX, amplification was observed, and an amplification product thereof was obtained. In the negative control solution MD, amplification of DNA was not observed, and an amplification product was not obtained. In solutions A, B, C and D of the unmethylated DNA fragment X, amplification was not observed, and an amplification product thereof was not obtained.

[0120] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and amplified DNA can be detected with higher sensitivity by amplifying methylated DNA to a detectable level.

EP 2 272 975 B1

Example 3

[0121] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylation kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 μg/μL solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO·7H₂O, 154 mM NaCl, pH 7.4)].

[0122] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μL of 0.1 μg/50 μL solution of the synthetically obtained biotin-labeled methylcytosine antibody was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0123] For genomic DNA derived from human blood purchased from Clontech, a DNA fragment (Y, SEQ ID NO: 43, a region corresponding to the base numbers 76606 to 76726 shown in Genbank Accession No. ac009800 and so on) to be used as a test sample was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) of SEQ ID NO: 42 and SEQ ID NO: 43 and the following reaction condition.

<Oligonucleotide primers designed for PCR>

[0124]

PF3: 5'-TGAGCTCCGTAGGGCGTCC-3' (SEQ ID NO: 41)

PR3: 5'-GCGCCGGGTCCGGGCC-3' (SEQ ID NO: 42)

<DNA fragment>

[0125]

Y: 5' -

GCGCCGGGTCCGGGCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC

TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCAAGGACGCCCTACGGAGCTCA-3'

(SEQ ID NO: 43)

[0126] As a reaction solution of PCR, 5 ng of genomic DNA which is a template, mixed with each 3 μL of oligonucleotide primer solutions prepared to 5 μM, each 5 μL of 2 mM dNTPs, 5 μL of a 10 × buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μL of 5 U/μL thermostable DNA polymerase (AmpliQ Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μL was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 50 cycles of incubation each including 30 seconds at 95°C, 30 seconds at 60°C, and 45 seconds at 72°C.

[0127] After conducting PCR, amplification of DNA was checked by 1.5% agarose gel electrophoresis, and a DNA fragment Y was purified with Wizard SV Gel/PCR Kit (PROMEGA).

[0128] For a part of the obtained DNA fragment solution, a reaction solution was prepared by mixing 1 μL of SssI methylase (available from NEB), 10 μL of a 10 × NEBuffer 2 (available from NEB), and 1 μL of S-adenosyl methionine (3.2 mM, available from NEB), and adding sterile ultrapure water to a liquid volume of 100 μL. The reaction solution was incubated at 37°C for 15 to 30 minutes, and further added with 1 μL of S-adenosyl methionine (3.2 mM, available from NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified with Wizard SV Gel/PCR Kit (PROMEGA). These operations were repeated another 5 times, to obtain a methylated DNA fragment (MY, SEQ ID NO: 44).

<DNA fragment> (N denotes 5-methylcytosine.)

[0129]

MY: 5' -

GNGCNGGGTCNGGGCCNGATGNGTTGGNNGGGCCAGGGCTCNGAGAANGAGGNGTTGTCCATC
 TCAANGAGGGCAGAGGAGCNGGNGACCTGGNGTCCCCCAAGGANGCCCTANGGAGCTCA-3'

(SEQ ID NO: 44)

[0130] For each obtained DNA fragment Y, the following solutions were prepared.

- Solution A: 100 pg/5 μ L solution in TE
- Solution B: 10 pg/5 μ L solution in TE
- Solution C: 1 pg/5 μ L solution in TE
- Solution D: TE solution (negative control solution)

[0131] For each obtained DNA fragment MY, the following solutions were prepared.

- Solution MA: 100 pg/5 μ L solution in TE
- Solution MB: 10 pg/5 μ L solution in TE
- Solution MC: 1 pg/5 μ L solution in TE
- Solution MD: TE solution (negative control solution)

[0132] For each of the solutions of the DNA fragment Y and the solutions of the methylated DNA fragment MY, the following treatment was executed.

[0133] Five (5) μ L of the DNA fragment solution prepared above was added with 2 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μ L of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μ L. Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

[0134] Counter oligonucleotides C13, C14, and C15 comprising the each nucleotide sequences of SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48 capable of complementarily base-pairing with a minus strand of the target DNA region Y' comprising the nucleotide sequence of SEQ ID NO: 45 were synthesized, and each 0.01 μ M solutions in a TE buffer were prepared.

<Target DNA region>

[0135]

Y' : 5' -

GCGCCGGGTCCGGGCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC
 TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCCAAGGACGCCCTACGGAGCTCA-3'

(SEQ ID NO: 45)

<Counter oligonucleotides>

[0136]

- C13: 5'-GCGTCCCCCAAGGACGCCCTACGGAGCTCA-3' (SEQ ID NO: 46)
- C14: 5'-CTCAACGAGGGCAGAGGAGCCGGCGACCTG-3' (SEQ ID NO: 47)
- C15: 5'-CGCCGGGTCCGGGCCCGATGCGTTGGCGGG-3' (SEQ ID NO: 48)

EP 2 272 975 B1

[0137] To the above reaction solution, 10 μL of a counter oligonucleotide solution prepared as described above, 5 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μL of a 100 mM MgCl₂ solution, and 5 μL of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μL , and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

[0138] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μL of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

[0139] Then by subjecting the above PCR tube to PCR using respective solutions of oligonucleotide primers PF3 and PR3 comprising the nucleotide sequences of SEQ ID NO: 41 and SEQ ID NO: 42, and the following reaction condition, methylated DNA in a target DNA region Y' comprising the nucleotide sequence of SEQ ID NO: 45 was amplified.

<Oligonucleotide primers designed for PCR>

[0140]

PF3: 5'-TGAGCTCCGTAGGGCGTCC-3' (SEQ ID NO: 41)

PR3: 5'-GCGCCGGGTCCGGGCC-3' (SEQ ID NO: 42)

<Target DNA region>

[0141]

Y' : 5' -

GCGCCGGGTCCGGGCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC

TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCAAGGACGCCCTACGGAGCTCA-3'

(SEQ ID NO: 45)

[0142] As a reaction solution of PCR, DNA which is a template, mixed with each 3 μL of oligonucleotide primer solutions prepared to 5 μM , each 5 μL of 2 mM dNTPs, 5 μL of a 10 \times buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μL of 5 U/ μL thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μL was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 25 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 60°C, and 30 seconds at 72°C.

[0143] After conducting PCR, amplification of DNA was checked by 1.5% agarose gel electrophoresis (these correspond to Third step of the present measuring method).

[0144] The result is shown in Fig. 3. In Solutions MA, MB and MC of the methylated DNA fragment MY, amplification was observed. In the negative control solution MD, amplification of DNA was not observed. In solutions A, B, C and D of the unmethylated DNA fragment Y, amplification of DNA was not observed.

[0145] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and amplified DNA can be detected with higher sensitivity by amplifying methylated DNA to a detectable level.

Example 4

[0146] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylating kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 $\mu\text{g}/\mu\text{L}$ solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM

EP 2 272 975 B1

KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}\cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)].

[0147] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μL of 0.1 $\mu\text{g}/50 \mu\text{L}$ solution of the synthetically obtained biotin-labeled methylcytosine antibody was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}\cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0148] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD_{600} 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1×10^7 of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0149] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 0.1% 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH_3COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH_3COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 $\mu\text{g}/\text{ml}$, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 $\mu\text{g}/\text{mL}$ and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

[0150] From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 51, a region corresponding to the base numbers 384569 to 384685 of yeast chromosome VII shown in Genbank Accession No. NC_001139 and so on) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 49 and SEQ ID NO: 50 and the following reaction condition.

<Oligonucleotide primers designed for PCR>

[0151]

PF4: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 49)

PR4: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)

<DNA fragment>

[0152]

T: 5' -

GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCC

GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

(SEQ ID NO: 51)

[0153] As a reaction solution of PCR, 10 ng of genomic DNA which is a template, mixed with each 3 μL of oligonucleotide primer solutions prepared to 5 μM , each 5 μL of 2 mM dNTPs, 5 μL of a $10 \times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl 15 mM MgCl_2 , 0.01% Gelatin), and 0.25 μL of 5 U/ μL thermostable DNA polymerase (AmpliAq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μL was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 40 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C.

[0154] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis, and a DNA fragment

EP 2 272 975 B1

T was purified with Wizard SV Gel/PCR Kit (PROMEGA).

[0155] For a part of the obtained DNA fragment solution, a reaction solution was prepared by mixing 1 μL of SssI methylase (available from NEB), 10 μL of a 10 \times NEBuffer 2 (available from NEB), and 1 μL of S-adenosyl methionine (3.2 mM, available from NEB), and adding sterile ultrapure water to a liquid volume of 100 μL . The reaction solution was incubated at 37°C for 15 to 30 minutes, and further added with 1 μL of S-adenosyl methionine (3.2 mM, available from NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified with Wizard SV Gel/PCR Kit (PROMEGA). These operations were repeated another 3 times, to obtain a methylated DNA fragment (MT, SEQ ID NO: 52).

<DNA fragment> (N denotes 5-methylcytosine.)

[0156]

MT: 5' -

GGACCTGTGTTTGANGGGTATAACACTAAGTTGNGCAATTTGCTGTATTGNGAAATCNGCCN

GGANGATATCACTCTTGAGNGCATGTGCNGTTTCNGAGAANGCCAGATCTGTACT-3'

(SEQ ID NO: 52)

[0157] For each obtained DNA fragment T, the following solutions were prepared.

Solution A: 100 pg/5 μL solution in TE

Solution B: 10 pg/5 μL solution in TE

Solution C: 1 pg/5 μL solution in TE

Solution D: TE solution (negative control solution)

[0158] For each obtained DNA fragment MZ, the following solutions were prepared.

Solution MA: 100 pg/5 μL solution in TE

Solution MB: 10 pg/5 μL solution in TE

Solution MC: 1 pg/5 μL solution in TE

Solution MD: TE solution (negative control solution)

[0159] For each of the solutions of the DNA fragment T and the solutions of the methylated DNA fragment MT, the following treatment was executed.

[0160] Five (5) μL of the DNA fragment solution prepared above was added with 2 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μL of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μL . Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

[0161] Counter oligonucleotides C16 to C19 each comprising the nucleotide sequences of SEQ ID NO: 54 to SEQ ID NO: 57 capable of complementarily base-pairing with a minus strand of the target DNA region T' comprising the nucleotide sequence of SEQ ID NO: 53 were synthesized, and each 0.01 μM solutions in a TE buffer were prepared.

<Target DNA region>

[0162]

T' : 5' -

GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCC

GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

(SEQ ID NO: 53)

<Counter oligonucleotides>

[0163]

- 5 C16: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 54)
 C17: 5'-AACACTAAGTTGCGCAATTTGCTGT-3' (SEQ ID NO: 55)
 C18: 5'-ATTGCGAAATCCGCCCGACGATAT-3' (SEQ ID NO: 56)
 C19: 5'-CACTCTTGAGCGCATGTGCCGTTTC-3' (SEQ ID NO: 57)

10 **[0164]** To the above reaction solution, 10 μ L of a counter oligonucleotide solution prepared as described above, 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of a 100 mM MgCl₂ solution, and 5 μ L of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L, and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this
 15 temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

[0165] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μ L of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μ L of a washing buffer [0.05% Tween 20-
 20 containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

[0166] Then the above PCR tube was subjected to PCR using respective solutions of oligonucleotide primers PF4 and PR4 comprising the nucleotide sequences of SEQ ID NO: 49 and SEQ ID NO: 50, and the following reaction
 25 condition, methylated DNA in a target DNA region T' comprising the nucleotide sequence of SEQ ID NO: 53 was amplified.

<Oligonucleotide primers designed for PCR>

[0167]

- 30 PF4: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 49)
 PR4: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)

<Target DNA region> (Also 5-methylcytosine is denoted by C.)

35 **[0168]**

T' : 5' -

40 GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCC
 GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

45 (SEQ ID NO: 53)

[0169] As a reaction solution of PCR, DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added
 50 with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 28 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C.

[0170] After conducting PCR, amplification of DNA was checked by 1.5% agarose gel electrophoresis (these correspond to Fourth step of the present measuring method).

55 **[0171]** The result is shown in Fig. 4. In Solutions MA, MB and MC of the methylated DNA fragment MT, amplification of DNA was observed, and an amplification product thereof was obtained. In the negative control solution MD, amplification of DNA was not observed, and an amplification product was not obtained. In solutions A, B, C and D of the unmethylated DNA fragment T, amplification of DNA was not observed, and an amplification product thereof was not obtained.

EP 2 272 975 B1

[0172] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and amplified DNA can be detected with higher sensitivity by amplifying methylated DNA to a detectable level.

5 Example 5

[0173] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylation kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 µg/µL solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)].

[0174] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 µL of 0.1 µg/50 µL solution of the synthetically obtained biotin-labeled methylcytosine antibody was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 µL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0175] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD₆₀₀ 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1 × 10⁷ of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0176] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 0.1% 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH₃COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH₃COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

[0177] Part of the obtained genomic DNA was mixed with 1 µL of SssI methylase (available from NEB), 10 µL of a 10 × NEBuffer 2 (available from NEB), and 1 µL of S-adenosyl methionine (3.2 mM, available from NEB), and added with sterile ultrapure water to a liquid volume of 100 µL. The reaction solution was incubated at 37°C for 15 to 30 minutes, added with 1 µL of S-adenosyl methionine (3.2 mM, available NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified by Wizard SV Gel/PCR Kit (PROMEGA). This operation was repeated three times, and methylated genomic DNA was obtained.

[0178] For the obtained yeast genomic DNA, the following solutions were prepared.

- Solution A: 10 ng/5 µL solution in TE
- Solution B: 1 ng/5 µL solution in TE
- Solution C: 0.1 ng/5 µL solution in TE
- Solution D: TE solution (negative control solution)

[0179] For the obtained methylated yeast genomic DNA, the following solutions were prepared.

- Solution MA: 10 ng/5 µL solution in TE
- Solution MB: 1 ng/5 µL solution in TE
- Solution MC: 0.1 ng/5 µL solution in TE
- Solution MD: TE solution (negative control solution)

[0180] For each of the above yeast genomic DNA solutions and methylated yeast genomic DNA solutions, the following treatment was executed.

EP 2 272 975 B1

[0181] A PCR tube was added with 5 μ L of the genomic DNA solution prepared as described above, 5 U of a restriction enzyme XspI, and 1 μ L of a 10 \times buffer (200 mM Tris-HCl pH 8.5, 100 mM MgCl₂, 10 mM Dithiothreitol, 1000 mM KCl) suited for XspI, and added with sterile ultrapure water to a liquid volume of 10 μ L. The reaction solution was incubated at 37°C for an hour.

[0182] The above solution was added with 2 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μ L of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μ L. Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

[0183] Counter oligonucleotides C16 to C23 each comprising the nucleotide sequences of SEQ ID NO: 54 to SEQ ID NO: 57 and SEQ ID NO: 59 to SEQ ID NO: 62, capable of complementarily base-pairing with a minus strand of the target DNA region T'(a region corresponding to the base numbers 384523 to 384766 of yeast chromosome VII shown in Genbank Accession No. NC_001139 and so on) comprising the nucleotide sequence of SEQ ID NO: 58 were synthesized, and each 0.01 μ M solutions in a TE buffer were prepared.

<Target DNA region>

[0184]

T' : 5' -

TAGGAAATACATTCCGAGGGCGCCCGCACAAAGGCCTATTATTAGAGGGACCTGTGTTTGACG
GGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCCGGACGATATCACTCTT
GAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACTGCGATCGCACACGAGGAGACACA
GCGTCACGTGTTTTGCCATTTTGTACGACAAATGAACCGCCTGGCCACGCCTCTAATC-3'

(SEQ ID NO: 58)

<Counter oligonucleotides>

[0185]

C16: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 54)
C17: 5'-AACACTAAGTTGCGCAATTTGCTGT-3' (SEQ ID NO: 55)
C18: 5'-ATTGCGAAATCCGCCCGGACGATAT-3' (SEQ ID NO: 56)
C19: 5'-CACTCTTGAGCGCATGTGCCGTTTC-3' (SEQ ID NO: 57)
C20: 5'-AATACATTCCGAGGGCGCCCGCACAAAGGCC-3' (SEQ ID NO: 59)
C21: 5'-GCGATCGCACACGAGGAGACA-3' (SEQ ID NO: 60)
C22: 5'-AGCGTCACGTGTTTTGCCATTTTGTACGAC-3' (SEQ ID NO: 61)
C23: 5'-AAATGAACCGCCTGGCCACGCCTCTAATC-3' (SEQ ID NO: 62)

[0186] To the above reaction solution, 10 μ L of a counter oligonucleotide solution prepared as described above, 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of a 100 mM MgCl₂ solution, and 5 μ L of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L, and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

[0187] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μ L of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

EP 2 272 975 B1

[0188] Then by subjecting the above PCR tube to PCR using respective solutions of oligonucleotide primers PF4 and PR4 comprising the nucleotide sequences of SEQ ID NO: 49 and SEQ ID NO: 50, and the following reaction condition, methylated DNA in a target DNA region T' comprising the nucleotide sequence of SEQ ID NO: 53 was amplified.

5 <Oligonucleotide primers designed for PCR>

[0189]

10 PF3: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 49)
PR3: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)

<Target DNA region>

[0190]

15
T' : 5' -
GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCC
20 GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'
(SEQ ID NO: 53)

25 **[0191]** As a reaction solution of PCR, DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaQ Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 31 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C.

30 **[0192]** After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis (these correspond to Fourth step of the present measuring method).

[0193] The result is shown in Fig. 5. In Solutions MA, MB and MC of methylated yeast genomic DNA, amplification of DNA was observed. In the negative control solution MD, amplification of DNA was not observed. In solutions A, B, C and D of unmethylated yeast genomic DNA, amplification of DNA was not observed.

35 **[0194]** From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and methylated DNA is amplified to a detectable level and the amplified DNA can be detected with higher sensitivity.

40 INDUSTRIAL APPLICABILITY

[0195] Based on the present invention, it becomes possible to provide a method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA contained in a biological specimen in a simple and convenient manner, and so on.

45 Free Text in Sequence Listing

[0196]

50 SEQ ID NO:17
Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)
SEQ ID NO:18
Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)
SEQ ID NO:19
55 Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)
SEQ ID NO:20
Designed oligonucleotide for experiment
SEQ ID NO:21

EP 2 272 975 B1

Designed oligonucleotide primer for PCR
SEQ ID NO:22
Designed oligonucleotide primer for PCR
SEQ ID NO:23
5 Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)
SEQ ID NO:24
Designed oligonucleotide primer for PCR
SEQ ID NO:25
10 Designed oligonucleotide primer for PCR
SEQ ID NO:26
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419
25687390-25687775 Homo sapiens)
SEQ ID NO:27
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419
15 25687390-25687775 Homo sapiens)
SEQ ID NO:28
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419
25687390-25687775 Homo sapiens)
SEQ ID NO:29
20 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:30
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:31
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
25 SEQ ID NO:32
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:33
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:34
30 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:35
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:36
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
35 SEQ ID NO:37
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:38
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:39
40 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:40
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:41
Designed oligonucleotide primer for PCR
45 SEQ ID NO:42
Designed oligonucleotide primer for PCR
SEQ ID NO:43
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.AC009800 76606-76726
Homo sapiens)
50 SEQ ID NO:44
Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.AC009800 76606-76726
Homo sapiens) n=m5c
SEQ ID NO:45
55 Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.AC009800 76606-76726
Homo sapiens)
SEQ ID NO:46
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:47

EP 2 272 975 B1

Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:48
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:49
5 Designed oligonucleotide primer for PCR
SEQ ID NO:50
Designed oligonucleotide primer for PCR
SEQ ID NO:51
10 Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685
Saccharomyces cerevisiae chromosome VII)
SEQ ID NO:52
Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685
Saccharomyces cerevisiae chromosome VII) n=m5c
SEQ ID NO:53
15 Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685
Saccharomyces cerevisiae chromosome VII)
SEQ ID NO:54
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:55
20 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:56
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:57
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:58
25 Designed oligonucleotide primer for PCR
SEQ ID NO:59
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:60
30 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:61
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA
SEQ ID NO:62
35 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQUENCE LISTING

[0197]

40 <110> Sumitomo Chemical Co., Ltd.

<120> Method for measuring DNA methylation

<130> N112271
45 <140> 09725639.0
<141> 2009-03-25

<150> JP2008-077967
50 <151> 2008-03-25

<160> 62

<210> 1
55 <211> 2661
<212> DNA
<213> Homo sapiens

<400> 1

	acagacatgt	gccaccatgc	ccagctaatt	ttttgtttgt	ttgtttgttt	gtttgtat	60
	ttagtagaga	tggggttttg	ccatggtggc	caggctggtc	tcgaactcct	gacctcgaat	120
5	gataatgatc	cgccgcttgg	cctccaaagt	gctaggatta	cagggtgtgag	ccactgcgcc	180
	aggcctgggc	actttcttta	gtagtttgag	gagcaacatt	tttgacagtg	tccttctgct	240
	caagattcaa	gatcccagat	aaaattaaac	catctagaga	gatggcttga	ttggccaaac	300
	ctggatctca	tgaccacttc	ttgaagtggg	taagtctcat	aaatgctcag	tccttccact	360
	atgcaactga	gtgggtggg	tgggaagccc	ctcaaaggaa	aatccggttg	ttcttactag	420
	aaagaaaagg	aaaatggatg	tgaggcagtc	aaaatcagca	gagggtccacc	acaccaccaa	480
10	aatgtggtga	ttaaatatgg	agagacagag	actaacagag	gtatgtgaat	attgaagtat	540
	gtctggacaa	tagcccaatg	atgagaccaa	taaaatgggt	accaaaatct	ggttttgagt	600
	agtagtgta	aatcagacca	tttagtaacc	atTTTTTgtt	gcaaagtttc	tagcactgcc	660
	caaacctga	gtggtatatg	aataactcgt	ccattatgta	tctctttcca	gtcagcataa	720
	tttatcccc	acctatattc	ttttctgacc	actcctactt	ccttctcttt	accaaaatct	780
	aaactctaa	gctgtttctt	cagcaacttc	tttgtttaga	ttggaagata	aattaaacag	840
15	caatgcatgt	tttactgact	ttcagtattt	aacagaggtg	atttaatttt	tttttaaatc	900
	caaatgcaaa	cttctttata	agatgaagga	gaaaaatgtc	ttataaaatg	catatgtgaa	960
	gatgccttct	gagtgccttc	tcatgcagac	ttgttctagt	ctttaatgaa	tcttctctgt	1020
	agacactgtg	gagatgaaag	atggttctcc	acttctactc	aaagtacaaa	tcaggccggc	1080
	atTTTgaaa	agagacaggt	ttattcatag	ctgcagcgtt	agctggcttt	gttccctgta	1140
	caatttcaact	tttggttatt	aaaatattca	ctgtaggaaa	taaatttgta	accattttct	1200
20	catattacct	acacacagaa	aaacaaaatt	tgatattcctg	gggtttattt	gctgagggcg	1260
	cttcccataa	aagcgagaga	gtgtgcgttg	ggaaatgtgt	ctggttaact	cttttatgga	1320
	taaactttag	tcacaatcct	ccccgcgcc	cctctcacc	ccagcaccct	cccaacctcc	1380
	cgacttccc	cctctcaagg	gctggtgacc	taatagcatt	tttcttcgtg	catatTTTgg	1440
	cgctgcctcc	tggcctggct	gccttcgcct	gtctgagttt	tttgaaatc	ctgcatgttc	1500
	gccccagatt	aagccagtgt	gtctcaggat	gtgtgttccg	ttttgttctt	tcccttaac	1560
25	gctccctgtg	caactgtct	ggggggagga	gggcagggac	gggagagagg	gaggggcaga	1620
	ggcgaggagc	tgccgcctt	gcacgtttcc	aatcgcatta	cgtgaacaaa	tagctgaggg	1680
	gcgccggggc	cagaacggct	tgtgtaactt	tgcaaacgtg	ccagaaagt	taaatctctc	1740
	ctccttctt	caactccagac	actgcccgt	ctccgggact	gcccgcggc	tccccgttgc	1800
	cttccaggac	tgagaaagg	gaaagggaag	ggtgccacgt	ccgagcagcc	gccttgactg	1860
	gggaaagggtc	tgaatcccac	ccttggcatt	gcttgggtga	gactgagata	cccgtgctcc	1920
30	gctcgcctcc	ttggttgaag	atTTTctctt	ccctcacgtg	atTTTgagccc	cgTTTTtatt	1980
	ttctgtgagc	cacgtcctcc	tcgagcgggg	tcaatctggc	aaaaggagtg	atgcgcttcg	2040
	cctggaccgt	gctcctgctc	gggcctttgc	agctctgccc	gctagtgcac	tgccgccctc	2100
	ccgcccgccg	ccaacagcag	ccccgcggc	agccgcggc	ggctccgggc	gcctggcgcc	2160
	agcagatcca	atgggagAAC	aacgggcagg	tgttcagctt	gctgagcctg	ggctcacagt	2220
	accagcctca	gcgcccgccg	gacccggcg	ccgccgtccc	tggtgcagcc	aacgcctccg	2280
35	cccagcagcc	ccgcaactcc	atcctgctga	tccgcgacaa	ccgcaccgcc	gcggcgcgaa	2340
	cgcgagcggc	cgctcatct	ggagtcaccg	ctggccgccc	caggcccacc	gcccgtcact	2400
	ggtccaagc	tggtactcgc	acatctagag	cccgcgaacc	tggcgctcgc	cgcgcgagaa	2460
	accagacagc	gccgggagaa	gttctgccc	tcagtaacct	gcggccgccc	agccgcgtgg	2520
	acggcatggg	ggcgagcagc	ccttacaacc	cctacaagta	ctctgacgac	aacccttatt	2580
	acaactacta	cgatacttat	gaaaggccca	gacctggggg	caggtagccg	cccggatagc	2640
40	gcactggcta	cttccagtag	g				2661

<210> 2

<211> 1953

<212> DNA

45 <213> Homo sapiens

<400> 2

50

55

EP 2 272 975 B1

tataaattcc acgcaggcat tgaattgaat ttgtttcttaa ccaaatgcgt tttatctata 60
 cctggcagga atctagaagt gaaattacaa gattttattc attttaattc tattatgaag 120
 catttaatca caaataccct gaaaatgaaa agataattha tcattttacc ttgactgagc 180
 aacttcctc acttcacatt catgaatcca taacgcagag aggagactgg atgattaagt 240
 5 gtttgattag agaaaacaga ttaacctagc aaacataata aatttggctc ataagcagga 300
 tggctttata aatgctcaca atacctctcc tgtataaaat catgaaccac ttctctacagt 360
 gatgactcca tcgaaatagt tgagaaacat aaagcaaatg catgtttatg gctttctctt 420
 tgagacatta aaagggtatt gaaaggcata tctgattcag cttataactc tggatatata 480
 ttaaggaaca tgtaagaaaa tattaatgca taaaaaaagc tacaacttct caagtgttct 540
 agtttccact ttgtcaataa ttacgttttc aatgtccttc tgtggactgt ttccaaaggt 600
 10 gccaatccag acccaaagtt tcagatcact cagattcacc cttaaccttc ataacacaac 660
 ccaatagctt tacgaaaaaa gttgcatatt taggtagtgg ttatcccatt atgacaaaat 720
 acataaaatt agcgagatat tttttagcct tcaaataagt gggaaaaaat ctttttagct 780
 gagattccat ttacatcaga ataaaaatct aagttatgac taggttgaag caacgtcctg 840
 tgcagcgctc cataaagttc acttagtctt caagggttcc ttacttagct aggttagtat 900
 tcctggcctc tttttttagc agtgagaaaa aggatactct ccctgcccc a gctttatfff 960
 15 taaactcaca gccatatcct ggaggtctct gctggctatt tggcgcgtgg gggcggaggg 1020
 gggccggggg agggggggcg ggcggggctt ggaggtctgt gctggctatc tggcgtgtgt 1080
 gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt aggtctctgc tggctatctg gcgtgtgtgt 1140
 gtgtgtgtgt tgggtgtgtgt aagcagttag gttgttttag ggccagtcct tcctccgcca 1200
 ctttgcagac tcaaagacc agaggcttcc ttgggggtgca ggtaccatga tccttggggc 1260
 cctaagggaa tttttgtag gctagaagag tgggtgtact catgatgggt gtaccggaac 1320
 20 attcctgggc tcaacaaaac cgattatctt tataaccgcg gcgcctagca cagcgcctgg 1380
 tgcctaaac gttggctgcy ggaacgtccg agacgcgggt gcggagccgg gggcggaaata 1440
 actggttgcg cggcgctttg accgtaggcg ctggagcgcg tgcgttgcgt gcgcgcgcgg 1500
 agggcgctgc gtcggggcgc gagaaggtgc agtccccgg cgggcggggc ggcggcgggg 1560
 cgaagctggg ctcggggcca agcgaggtct agccggagcg actgtgcccc gcctcctggg 1620
 cggagcgggc ggctccccat ggtcagagcc tcgtgccggc tcggcagcgc ccggacgccg 1680
 25 agcccagcgc gtcggccccc cggcgtgcyg gcgtctcaga gccgcggagg gcccgcgggg 1740
 accgtttcag cgtggcggcg ctggtgctgg cgttggccct ggaggacggc cccgagtgat 1800
 ggctggcgcg tgcctcccgg gtgtctcccg ggtacagatg gagtctgccc gcggccgccc 1860
 gcggcaaggt cggcagctgc cggcaagga gagaccccag gacacacaca gctgcectccc 1920
 ggtgcgagaa gaagaccccg gcttgagagt gag 1953

30 <210> 3
 <211> 889
 <212> DNA
 <213> Homo sapiens

35 <400> 3

cggccccatg gctccgtgct gtgtccaagg gatgggctgg cacctcttgg accaggctta 60
 ccaccagggc ccttctctga agccccagtc tgaccggcct gctgctggga atccccctct 120
 gccccacac taacctctgc tggggctgag ccagggcgcy tcggacagtc agggcgacct 180
 40 agccagggcg accggtggcc ccgctcctat gggcagcag ggaccgact cagcagggtg 240
 gggcgggac ccgagtggta tgccccgccc tgccccgct gcccggcctg gtggcctct 300
 gggggcgaca agtcctgaga gaaccagacg gaagcgcgct gggactgaca cgtggacttg 360
 ggcggtgctg cccgggtggg tcagcctggg ctgggaggca gccccgggac acagctgtgc 420
 ccacgcccgc tgagcacccc aagcccgatg cagccacccc cagacgaggc ccgcagggac 480
 atggccgggg acaccagtg gtccagggtg ggcgggggtg aggggagggg ggggtggagc 540
 45 ggtggagatg gggccgtggg gagggagctg agatactgcc acgtgggacg atgctaggtg 600
 gggagggtg agctgggcyg gctcctctgg ctgtggggcc ccctgtgttc cttgtgggag 660
 gtggaaggaa gtgagtgcct tgccttctc cctgcccag agattccagg accggacctg 720
 gcaagtgcct tatcccagcc agtgttctct gggctcttcc aggcagggt atgttcccca 780
 ggccaggggc attgtcctgg acagtcagga ggcatacccc tcgccagggt gaaccaccc 840
 50 gtgtatgcat gaccctgaca agcaggcgcc aggcagctca ggaggccag 889

50 <210> 4
 <211> 863
 <212> DNA
 <213> Homo sapiens

55 <400> 4

EP 2 272 975 B1

5
 10
 15
 20

gttgttgggt	gtgaatggag	aactgtgggc	cctccccgac	accttccagc	gggacggcaa	60
cgggggcccc	gggggtgggc	gccatcaacc	ccgtcccacc	gccaggacgg	cgcgggggag	120
ggccggcggg	ggcgggcggt	cctgtaaggc	gcggccccc	cccgcgggcg	gggcggcatt	180
cctgggaggg	cgcgctctg	acgtggacc	gggggcccgc	ggcacggcgg	ggggcgggcg	240
gtccgggggc	ttcttaaacc	ccccgcccg	gcccagcccg	cacttcccga	gcaccgctcc	300
gaccctggag	ggagagagag	ccagagagcg	gcccagcgc	taggaggccc	gccgagcctc	360
gccgagcccc	gccagccccg	gcgcgagaga	agttggagag	gagagcagcg	cagcgcagcg	420
agtcccgtgg	tcgcgcccc	acagcgcgg	acagcccccg	atagcccaaa	ccgcggccct	480
agccccggcc	gcacccccag	cccgcgccag	catgatgaac	aacagcggct	actcagacgc	540
cgccctcggc	ctgggcgatg	agacagacga	gatgccgtcc	acggagaagg	acctggcggg	600
ggacgcgccc	tggagaaga	tccagcagaa	gcatttcacg	cgctggtgca	atgagcacct	660
caagtgcgtg	ggcaagcgcc	tgaccgacct	gcagcgcgac	ctcagcgcag	ggctccggct	720
catcgcgctg	ctcagaggtg	tcagccagaa	gcgcattgtac	cgcaagtcc	atccgcgccc	780
caacttccgc	caaatgaagc	tggagaacgt	gtccgtggcc	ctcgagtcc	tcgagcgcga	840
gcacatcaag	ctcgtgtcca	tag				863

15 <210> 5
 <211> 2198
 <212> DNA
 <213> Homo sapiens

20 <400> 5

25
 30
 35
 40
 45
 50

aagagaggca	cactccctct	accacaccga	gggagggggc	gttgagctga	gaaaggttga	60
gagaatgagg	gaccaggtta	ggtggacatc	ggccaagaaa	ggaaccacag	cgggaggtaa	120
gaccgagagt	ccccagcttg	aagcgtcacc	actccgggat	tcccagattc	caacgcgagc	180
ctggggaaaag	cccacagtgg	agagagtccg	gctggcaggg	aatggcccta	ccccgggggt	240
gaaatctcgg	agggtcgtgc	agccgagtcg	gcctctgcg	ctgatgcgtg	agagatgccg	300
gacgtcgcgt	ttgcctgtgc	gagcctcgcg	gatgctgtgc	agtcttggtc	ccctctgcgt	360
gtgtctaacg	ccgaatgctg	gtgtctcgag	gtgtgagctt	cggggcccgt	gtctttaaag	420
aaccaaagat	tcttaaggag	tgatgatctg	ggtagagcgg	cccagcgtag	ccgcgctccc	480
aggtctcggg	cgagtcctg	cggacagacc	agaggagacc	tgctggccc	atgccccggg	540
cccaaggcgg	acgccagact	gtctctgcg	cagccgggct	ggccttcgga	atggatcagg	600
cacccgggag	gccggagtgg	atctcagacc	ctcaagccgg	gaacaaacc	gtcgatgcc	660
gtgggcctgg	agtccgcctc	ctcctcccc	ccccaccct	accctgcct	ccgaaaggct	720
tcttcgctgg	tcagtagctg	cgtgcccgtc	tgccctgaggc	tgggtcagaa	ttggcgggct	780
ggtaacgacc	ccgtgcacaa	gcggtccca	gtctctccag	aaagggccga	tgactaaggg	840
gtgggggtgg	ggcgggaggg	ctggaaggtg	ttagggaaaga	acgttagcgg	cctatcctgt	900
cttcagcagc	gccctctcat	cttctagctc	tgacgccgag	cagagcagtt	ggagctcggg	960
actgggaact	gctggaattc	ctatttagac	ttctagacag	tctagaaaca	agaacctttc	1020
ttccctggg	cctcagtttc	cttgtctgta	aatcaaaaag	gcgggctcta	ggtgtaggcc	1080
ttcttttcgc	ttgggtgattc	tggattcctt	tccttggatc	cgtggggagg	gggtggcagc	1140
aacagtcacg	ggcgttggcc	gtcctgtgcc	tcaagtacgt	agtccccgtg	ccccccccct	1200
caacaccccc	agcagccccg	ccccctaagc	ccgcagagca	gggagctgag	tgggaggggc	1260
agagggcggg	ccggttccca	gtccctgctg	gcggactaga	gtggcgcggg	ctgagcgtaa	1320
aacctgggat	agccactccc	ccttttcctt	atccccgcc	ccctgccatt	ggctcccggg	1380
agaggttgac	atcaaagccg	cggcttata	taagccagat	ccgcagggga	gtccgcagaa	1440
gggttaaaca	ggtcttggg	cttcggcgac	ctcggccgcg	gcagaaaccg	gtaagaagac	1500
agtgggctgc	gcgtctcatt	ttcagccttg	ccccgactct	cccaaagccg	gcgccagta	1560
gtggctccag	agcccacagg	tggccccgg	cagtctctgg	ggcgcatgga	gcggcgtaa	1620
tagggctggc	ggcgcaggcc	agtagccgct	ccaacatgaa	cctcgtgggc	agctacgcac	1680
accatcacca	ccatcaccac	ccgcacccctg	cgcaccccat	gctccacgaa	cccttctct	1740
tcgggtccggc	ctcgcgctgt	catcagggaa	ggccctactt	ccagagctgg	ctgctgagcc	1800
cggtgacgc	tgccccggac	ttccctgctg	gcgggcccgc	gcccgcggcc	gctgcagccg	1860
ccaccgccta	tggtcctgac	gccaggcctg	gcagagccc	cgggcggtg	gagcgcttg	1920
gcggccgtct	tggccggcgg	aaaggctcag	gacccaagaa	ggagcggaga	cgactgaga	1980
gcattaacag	cgatttcgcg	gagttgcgcg	agtgcatccc	caacgtgccc	gccgacacca	2040
agctctccaa	gatcaagact	ctgcgcctag	ccaccagcta	catcgcctac	ctgatggagc	2100
tgttgccaa	ggatgcacag	tctggcgatc	ccgagccctt	caaggctgaa	ctcaagaagg	2160
cggatggcgg	ccgtgagagc	aagcggaaaa	gggagctg			2198

55 <210> 6
 <211> 1945
 <212> DNA
 <213> Homo sapiens

<400> 6

5	ctggatgaca	gagtgagact	ccgtctcaaa	aaaaagctc	catttgggag	gccgaggagg	60
	gtggattacc	tgaggtcagg	agtttgagac	cagcctggcc	cacatagga	aaccctatct	120
10	ctactaaaa	tacaaaaatt	agtcaggtgt	ggtggctgac	acctataatc	ccagctactt	180
	gggaagctga	ggcagggaga	atcacttgaa	ccggggagggt	ggaggttgca	gtgagctgag	240
	atcatgccac	tgcactccag	cctgggcgac	agggtgagat	tctgtctcaa	acaaacaaat	300
	ttaaaagctc	cgaatcctcc	aaaaatacca	agattttcct	gtcggtaact	agagatgggt	360
	actgatgatt	atTTTTaata	ggtgattttc	aaagatgtga	acgttatcca	tggagattta	420
	agtctccaaa	aggaaaaaaa	atgcatacct	ttatactaaa	acttcatcac	cagtcaaatt	480
	tggatcatca	ctaaattggc	ttctacacct	ctctccta	ataaggtact	tgtgtaagtt	540
	tgcagttgtg	agacacttat	ttcctcattt	ttaatgtctt	ctcagtaggg	ccactgat	600
15	agtcactatt	tgactgacca	gaatggttgg	cactgggtgat	tggctcataa	agtGCCctcg	660
	atthaggggg	ctcaattatc	aaagggttaa	atcctagccc	aaaccattgc	tgtgatgggg	720
	gttaatcaat	gaaccactca	gcttcacttg	caaaagcggg	atcacaatag	ccgctttcgt	780
	catgacccag	cctaggtgag	atthagttact	taagtacact	gccaggcaca	caaggtta	840
	ttaacaattt	aacacatttg	tttctcctc	catttctcca	aaccttcca	ctaactccta	900
	cgttcgttcc	gccaaatggg	ccaggaattc	acttaaaca	aaacaaaaa	caaaacaaac	960
20	aaaaaacac	tccctggggc	ttggggaagg	aggcaccgcc	gcccatgtcg	cagctggggg	1020
	gtggctcagt	cctcagcacc	cagatctacg	gccataatgc	tcttcgaggc	caaggagccc	1080
	ggatgcgggg	cgttgccgaa	ggcgtcttgc	tcaggctgcg	ggaaaggaga	ggggtgggag	1140
	cggggtgggg	gcatcgcgac	ccagggcaag	gcggcgagtc	gccgtcttcg	agtcccacct	1200
	gtccgaagcg	gggtgagaaa	aggcaaaaca	tggcaaagcc	atgcacctcc	cagggtgggc	1260
	aactcacggc	cgggtgaacgc	cggaccctta	gcagtttcca	gacctttgga	accggaagcg	1320
25	gagcctgaga	gcgcgcccga	gagggcgtga	acgggaccgc	tttcccggaa	gtgcttgccg	1380
	cctctgccc	gcgagctgcc	ccgggggtctc	tctggtttcc	taatcagggc	aacgccgcgg	1440
	gagagaacct	ttaccttggc	tgactaagt	tctcgggtgcc	actccctggc	agggcgggac	1500
	cttgttttag	ccctgtgatc	gcgcggttcg	tagtagcgca	aggcgcagag	tggaccttga	1560
	cccgcctag	gcgggaagag	tttggcccgc	cgggtcccaa	agggcagaat	ggcgggctc	1620
	ctaaatccca	gggaatcctc	taaattcatt	gcagaaaaca	gtcgggatgt	gtttattgac	1680
30	agcggaggcg	tacggagggt	ggcagagctg	ctgctggcca	aggcggcggg	gccagagctg	1740
	cgcgtaggag	ggtggaaaagc	ccttcatgag	ctgaacccca	ggcggccga	cgaggccgcg	1800
	gtcaactggg	tgttcgtgac	agacacgctc	aacttctcct	tttggtcgga	gcaggacgag	1860
	cacaagtgtg	tggtgaggta	cagagggaaa	acatacagtg	ggtactggtc	cctgtgcgcc	1920
	gccgtcaaca	gagccctcga	cgaag				1945

35 <210> 7
 <211> 2379
 <212> DNA
 <213> Homo sapiens

40 <400> 7

45

50

55

EP 2 272 975 B1

5 aagcttgtgg tttacttggg cctctgcctc atctttcttc ttttgcgctt cagcctgcgc 60
 attcgcttcc tccactaggg tctcatgggtg cagaggttcc caagaagatg gtgtgaaggc 120
 cgagatcatt tgggtatatt ataaaataga atgcaaatcc acacaagttt ttgtttttta 180
 tttatatttt ttttttagaga tgagggtcttg ctatgttgtt tagtctggtc tcgaactcct 240
 ggccctcgtga tcctcccacc ttgacctccc aaagtgcctgg gattacaggg ctgaggcctg 300
 agccactaca cccaactgaa ttcacatttt ttttttctt ttctgagacg gagtctcact 360
 ctgtcaccca gtatggagtg cagtggcgcg actgcggctc actgcaagct cegtctctcg 420
 ggttcaagtg attctcatgc ctcagcccc caagttagctg gaattacagg ggtgactac 480
 cacacctggc taatttttct gtttttagtag agatgggggt tcaccatggt gcctggctc 540
 aaactcctga ctttaagtga tccacacacc tcagcctccc aaagtgcctgg gattacaggt 600
 10 gtgagcctcc acaccggcc gaattcacat gaattttaa gtgatgtctt caaagtgggt 660
 tcactgtggg gatgggcagc tttttgttat acatctagaa cgttcctctt ctgttctat 720
 gaatactcgg ttggaagggt ctgaaaaacg gtcttaagag attatctgat tcgtttccca 780
 gttttattac tcacatatca gctgtaattt gagcacgttt tctgattgag acaagactca 840
 gatggtatta aacattacta caacacatcc gggcacgggt gctcacgctt gtaatcccag 900
 cactttggga ggccgagggc ggcggatcac gaggtcagga gatcgagacc atcctggcta 960
 15 acacggtgaa gccctgtctc tactaaaaat acaaaaaatt aggcgggcat ggtggcggc 1020
 gcctgtagtc ccagctactc gggaggctga ggcaggagaa tggcgtgaac ccgggagggc 1080
 gagcttgag tgagccgaga tcgcccact gcactccagc ctggcgaca gagcaagact 1140
 ccatctcaaa aaaaaaaaaa aaaaaaaaaa actacaacac tataaattca tatctattat 1200
 aatagtactt tgtgcagggc cctaccctaa gtccctaac gaaccggaa gcgagaagat 1260
 20 gaactttgtt tgtttttaga gatgggcgcc tggctctgtc gccagcctgg agtgtgggg 1320
 cgcgatctcg actcacagca gcctccacct cccgagttca ggcgatctc ctgctcagc 1380
 cctcagagg gctgggacca ccggcgcgct ccctcgcgcc cggctaggag ctgactttga 1440
 atccgggctc tgcgectggc ctctctgatc tctataaggg aagacatctg tgacctcggg 1500
 gcaaaggta aattagatcc tgggtaggat cctgttcccg ctgcccctcg ggctggcact 1560
 gccagagta ctcagagctc aaagctggga tctgcagtcc cttaccact cagtgcagc 1620
 25 gcctaaggc tttgcgctc acctttactc acctcgaagc cctggacatc cgcctctgcc 1680
 ctaagacttc tcacctcagt agcagaagga agtcggtca gctggccaca gcctctctcc 1740
 taggagaccg tccgggaaaa gcgagtcagg gttagaccctg aggcacctca gctccggcta 1800

30 ttttcagatc tgtcgctcct tcaccctcag cctttcaaac aggcactcc aaaaaaaaaagc 1860
 ccaatcacag ccttccttct tctcctggcc ttccggcact gtccaatcaa cgtacgcat 1920
 ctatcgggta tgggtgttgc ggggccaccc ttcccgctgg tttcctcgt ggtgtgtaaa 1980
 ggcagagagg aaaggcgagg ggtgttgacg ccaggaaggt tccatcttg ttaagggcag 2040
 gagtccctta cggacttgtc tgaggaaaga caggaaagcg ccagcatctc cacctcccc 2100
 ggaagcctcc ctttgccagg cagaaaggggt ttccatggg gccgcccctg gcgcccgcgc 2160
 cggcccacgt acccggggag gccgggcccc ggaggacgag ggaagcagg ccgggcccgc 2220
 35 tgagcttggc ggacgtggcc gtgtacttct ctcccagga gtgggaatgc ctgcccagcag 2280
 cgagagggc cctgtaccgg gacgtgatgc gggagacctt cggccacctg ggcgctctg 2340
 gtgaggccgg gccctcggc cgggaccccc agtccgctg 2379

<210> 8
 <211> 933
 40 <212> DNA
 <213> Homo sapiens

<400> 8

45 gagacgtact ctggctctgt cgcccaggct ggagcgcaat ggcgcatct cggcgactg 60
 caacctccac ctcccgggtt caagcgattc tactgcctca gcctcccag tagctgggac 120
 tacaggcgcg cactaccaag cccggtaat ttcttttga ttttttagtag agactgggtt 180
 tcacgatggt ggccgggctg gtctggaagt cttgacctca agcgtgcgcc ctctccgcca 240
 ctgggtaagg cggggggcgg aatagggggc ttgcaatttc aactagagg cggcgccgt 300
 50 ggggaaaga agagtcacgt ctcccaggt tcgtagagga aggcctgcct gagcctggag 360
 cgggggcccgg agagccacag tttggcatcc ccagggcatc cccagcccg cagactacca 420
 ggcctccaga ggacaggacc ccacccccgg ccacaggccc tgccccagc actccccgca 480
 ccccgctcc aagactcctc cgcccactcc gcaccacta tataaaaacc gtcctcggg 540
 gcggcgggga gaagccgagc tgagcggatc ctacacgac tgtgatccga ttctttccag 600
 cggcttctgc aaccaagcgg gtcttaccct cggctcctcg cgtctccagt cctcgcact 660
 55 ggaaccccaa gteccccgag agtccccgaa cccccgctcc caggctacct aagaggatga 720
 gcggtgctcc gacggccggg gcagccctga tgcctctgcgc cgccaccgcc gtgctactga 780
 gcgctcaggg cggaccctg cagtccaagt cgccgcgctt tgcgtcctgg gacgagatga 840
 atgtcctggc gcacggactc ctgcccctcg gccaggggct gcgcaaacac gcggagcgca 900
 cccgcagcca gctgagcgcg ctggagcggc gcc 933

EP 2 272 975 B1

<210> 9
 <211> 6096
 <212> DNA
 <213> Homo sapiens

5

<400> 9

	atctgcacct	cctcatatag	ggttgatcca	agtttcacag	acatcactga	gttcttagtg	60
	gactcagcta	ttggggctgt	tctcacactt	ttttttctt	tgcaagaatc	agcaatgggt	120
10	gcaagtggac	ctgtgtagga	cgtccagtga	aacattgtgt	tggtgaatca	gctagaatcc	180
	atccaagaac	tcagccagcc	tggtgtgggg	tgagatctga	tccttgaatg	tcctcagtg	240
	gcttttaggg	ctggcagggt	cagaagggcc	ctctcatcac	ccccccaggg	cctcattcct	300
	tgtttaacac	tttgcataca	cagtcttgaa	tccttgaat	tgaacaatgg	acccccacatt	360
	ttcactttgc	actggtttct	gattctgtaa	cggatcctgt	ccccctctct	tgtctcattc	420
	actctgggaa	ttgtccccac	attctgagac	ctttcagcag	tgccccaacg	aggttcctgc	480
15	ccttatctga	agctccaccc	tcacccccat	ggcggcaccg	caggcagccc	tgcttttgcg	540
	tcccgcgtag	gcaggctgtg	caccggagtc	acgacccccct	gattcagcct	aggcagccac	600
	agcttgactg	ctccccgccg	acaagcccta	ctgtgctatc	tgccgctctt	cccttcctct	660
	tcccaggggg	tccgcgctcag	gggaggcgca	gctgtgtgca	ttccgggagc	ttcagacccc	720
	cgtgtccagc	agctccttcg	tttctctgggt	gctggggcgg	ccttcccagc	gaagagctca	780
	actcagcggg	acgtttggag	gctctctgcc	ccaaggcgct	ggggagtgtg	cggcgggaca	840
20	gtcgtgcttg	cctttttcac	tttcagagtg	tccacgcccc	accggttgg	tactgcagg	900
	tcagtccagt	ccagcccggc	ccacccccacc	ggtgcgtgtc	tgtcgcacgt	ggcagacgcc	960
	atactctctg	ttcttgttta	aagcccagga	tctactgggc	cctggaggca	agaggtgaac	1020
	gcagcggaat	ccacgctgag	ctgccccgga	acggagcttc	caaccccaga	aggaggactc	1080
	tgtgctccta	caccttaacc	cttttttagcc	cgaaacttct	ccaacttct	tggctttgtt	1140
	tagagctcga	cagcgccgcc	ccctggcgct	cgttgtgagg	acagtagagg	agagaggcaa	1200
25	gggtgttttt	aaacagtttg	cctctcacca	ttatgggggc	gacccgaggg	ggagaccac	1260
	tcttccgcat	tcccggtaag	tgaaccaccg	gaagaggctc	aaagtgacgg	attcccatgt	1320
	cctcctccag	cccccccccc	accctgccca	tccacaggac	ggtggctctt	cagtgcctt	1380
	tgccgagcaa	gtggcgtttc	tatgcacgtg	ggtatcaatt	cggactctgg	acgaaatgga	1440
	aacctcctta	gccgacccgg	gtgggatcag	ctgggatcct	gcgcgctccc	ctgggggggt	1500
	gccagccact	ctggtgggg	gcaagaagca	ccatccttcg	gaagctgggc	cgaaactggc	1560
30	caggctgact	cgctcccacg	cgcccccccc	tacccggcgc	cgcagcaatt	cacctgccac	1620
	cgctctgag	ccgggtccgg	acttcggcgc	cctgacagtg	tccccgcgac	ttccccacc	1680

35

40

45

50

55

	gatgagatgg	ggtctggcgt	tggccagtgc	gtgtccaggg	actcgcgggt	ccctggccag	1740
	ccatggggca	gagggcgctg	gtgttaggcc	agtcttcccc	accctgcccc	gtcaccaccag	1800
	ccacaccac	tgtcctgtga	ggccaagcgc	gctccgctgg	tttctgagc	caggcacctt	1860
	ggccgcggag	aggatccagc	tgctctcct	tgcgatcctg	tcttcgggga	agtccaagtc	1920
5	ctaggcaggt	cctcccaaag	tgcccttggg	gcgatcacc	cctcccagcg	tcttgacaggt	1980
	cctgtgcacc	acctcccca	ctccccatte	aaagccctct	tctctgaagt	ctccggttcc	2040
	cagagctctt	gcaatccagg	ctttccttgg	aagtggctgt	aacatgtatg	aaaagaaaga	2100
	aaggaggacc	aagagatgaa	agagggtcgc	acgcgtgggg	gccccagtg	tgggcgggga	2160
	cagtcgtctt	gttacagggg	tgctggcctt	ccttggcgcc	tgccccctgc	ggccccgcc	2220
	gagaacctcc	ctgcgcccagg	gcagggttta	ctcatccccg	cgaggtgatc	ccatgcgcga	2280
10	gggcgggcgc	aagggcgggc	agagaaccca	gcaatccgag	tatgcccgat	cagcccttcc	2340
	caccaggcac	ttccttcctt	ttcccgaacg	tccagggagg	gagggccggg	cacttataaa	2400
	ctcgagccct	ggccgatccg	catgtcagag	gctgcctcgc	aggggctcgc	cgcagcgga	2460
	agaagtgtct	gggctgggac	ggacaggaga	ggctgtcggc	atcggcgtcc	tgtgcccctc	2520
	tgctccggca	cggccctgtc	gcagtccccg	cgcttcccc	ggcgctgca	cggcgccgc	2580
	ctgggtaaca	tgcttggggg	cctggtcctt	ggcgcgctgg	ccctggccgg	cctgggggtc	2640
15	cccgcacccg	cagagccgca	gcccgggtgg	agccagtgcg	tccagcacga	ctgcttcgcg	2700
	ctctaccggg	gccccgcgac	cttctcaaat	gccagtccga	tctgcgacgg	actgcggggc	2760
	cacctaata	gactgcgctc	ctcgggtggc	gccgatgtca	tttcttggc	actgaacggc	2820
	gacggcgggc	ttggccggcg	gcccctctgg	atcggcctgc	agctgccacc	cggctcgggc	2880
	gacccaagc	gcctcggggc	cctgcgcggc	ttccagtggg	ttaccgggga	caacaacacc	2940
	agctatagca	ggtgggcacg	gctcgacctc	aatggggctc	ccctctcggg	cccgttgtgc	3000
20	gtcgtgtct	ccgctgctga	ggccactgtg	cccagcgagc	cgatctggga	ggagcagcag	3060
	tgcgaagtga	aggccgatgg	cttctctcgc	gagttccact	tcccagccac	ctgcaggcca	3120
	ctggctgtgg	agcccggcgc	cgcggctgcc	gcccctcoga	tcacctacgg	caccocgttc	3180
	gcgcccgcg	gagcggactt	ccaggcgtc	ccggtgggca	gctcccgccg	ggtggctccc	3240
	ctcggcttac	agctaagtgt	caccgcggcg	cccggagcgg	tccaggggca	ctgggcccagg	3300
	gagcgccgg	gcgcttggga	ctgcagcgtg	gagaacggcg	gctgcgagca	cgctgtcaat	3360
25	gcgatccctg	gggctccccg	ctgccagtgc	ccagccggcg	ccgccctgca	ggcagacggg	3420
	cgctcctgca	ccgcatccgc	gacgcagtc	tgcaacgacc	tctgcgagca	cttctgcggt	3480
	cccaaccccg	accagccggg	ctcctactcg	tgcatgtgcg	agaccggcta	ccggctggcg	3540
	gccgaccaac	accggtgcga	ggacgtggat	gactgcatac	tggagcccag	tccgtgtccg	3600
	cagcgtgtg	tcaacacaca	gggtggcttc	gagtgccact	gctaccctaa	ctacgacctg	3660
	gtggagcggg	agtgtgtgga	gcccgtggac	ccgtgcttca	gagccaactg	cgagtaccag	3720
30	tgccagcccc	tgaaccaaac	tagctacctc	tgcgtctcgc	ccgagggctt	cgcccctatt	3780
	ccccacgagc	cgacaggtg	ccagatgttt	tgcaaccaga	ctgcctgtcc	agccgactgc	3840
	gacccaaca	cccaggctag	ctgtgagtgc	cctgaaggct	acatcctgga	cgacggtttc	3900
	atctgcacgg	acatcgacga	gtgcgaaaac	ggcggttct	gctccggggg	gtgccacaac	3960
	ctccccggta	ccttcgagtg	catctgcggg	cccgactcgg	cccttggccc	ccacatggc	4020
	accgactgtg	actccggcaa	ggtggacggg	ggcgacagcg	gctctggcga	gccccggccc	4080
35	agcccagcgc	ccggctccac	cttgactcct	ccggccgtgg	ggctcgtgca	ttcgggcttg	4140
	ctcataggca	tctccatcgc	gagcctgtgc	ctggtgggtg	cgcttttggc	gctcctctgc	4200
	cacctgcgca	agaagcaggg	cgccgccagg	gccaaagtgg	agtacaagtg	cgcgccccct	4260
	tccaaggagg	tagtgctgca	gcacgtgcgg	accgagcgga	cgccgcagag	actctgagcg	4320
	gcctccgtcc	aggagcctgg	ctccgtccag	gagcctgtgc	ctcctcacc	ccagccttgc	4380
	taccaaagca	ccttagctgg	cattacagct	ggagaagacc	ctccccgcac	ccccaaagct	4440
40	gttttcttct	attccatggc	taactggcga	gggggtgatt	agagggagga	gaatgagcct	4500
	cggcctcttc	ctgtgacgtca	ctggaccact	ggcfaatgat	ggcaattttg	taacgaagac	4560
	acagactcgc	atthgtccca	ggtcctcact	accgggcgca	ggaggggtgag	cgttatttgg	4620
	cggcagcctt	ctgggcagac	cttgacctcg	tggctaggg	atgactaaaa	tatttatttt	4680
	ttttaagtat	ttaggttttt	gtttgtttcc	tttgttctta	cctgtatgtc	tccagtatcc	4740
	actttgcaca	gctctccggg	ctctctctct	ctacaaactc	ccacttgtca	tgtgacaggt	4800
45	aaactatctt	ggtgaatttt	tttttcttag	ccctctcaca	tttatgaagc	aagccccact	4860
	tattccccat	tcttcctagt	tttctcctcc	caggaactgg	gccaactcac	ctgagtcacc	4920
	ctacctgtgc	ctgaccctac	ttcttttggc	cttaagctgtc	tgctcagaca	gaacccctac	4980
	atgaaacaga	aacaaaaaca	ctaaaaataa	aaatggccat	ttgctttttc	accagatttg	5040
	ctaatttatc	ctgaaatttc	agattcccag	agcaaaataa	ttttaacaa	aggttgagat	5100
	gtaaaaggta	ttaaattgat	gttgctggac	tgcatagaa	attacaccca	aagaggtatt	5160
	tatctttact	tttaaacagt	gagcctgaat	ttgtttgctg	ttttgatttg	tactgaaaaa	5220
50	tgtaattgt	tgctaactct	cttatgcaat	ttcctttttt	gttattatta	cttatttttg	5280
	acagtgttga	aaatgctcag	aaggttgctc	tagattgaga	gaagagacaa	acacctccca	5340
	ggagacagtt	caagaaagct	tcaaaactgca	tgattcatgc	caattagcaa	ttgactgtca	5400
	ctgttccttg	tcactggtag	accaaaataa	aaccagctct	actggtcttg	tggattggg	5460
	agcttgggaa	tggatcctgg	aggatgcccc	attagggcct	agccttaatc	aggtcctcag	5520
	agaatttcta	ccatttcaga	gaggcctttt	ggaatgtggc	ccctgaacaa	gaattggaag	5580
55	ctgcccctgc	catgggagct	ggttagaaat	gcagaatcct	aggctccacc	ccatccagtt	5640
	catgagaatc	tatatttaac	aagatctgca	gggggtgtgt	ctgctcagta	atthgaggac	5700
	aaccattcca	gactgcttcc	aattttctgg	aatacatgaa	atatagatca	gttataagta	5760

EP 2 272 975 B1

5 gcaggccaag tcaggccctt attttcaaga aactgaggaa ttttctttgt gttagctttgc 5820
 tctttggtag aaaaggctag gtacacagct ctagacactg ccacacaggg tctgcaaggt 5880
 ctttggttca gctaagctag gaatgaaatc ctgcttcagt gtatggaaat aaatgtatca 5940
 tagaaatgta actttttgtaa gacaaagggt ttctctctct attttgtaaa ctcaaaatat 6000
 ttgtacatag ttattttattt attggagata atctagaaca caggcaaaat ccttgcttat 6060
 gacatcactt gtacaaaata aacaaataac aatgtg 6096

<210> 10
 <211> 2500
 <212> DNA
 <213> Homo sapiens

<400> 10

15 acccacttct gtgtgtggat agtatcctgc aggagagatg ttgtctgcag tgtgagctgg 60
 gcccaccgga gtgtgtgaat aggatcctgc aggagaaatg gaatccggag tgtgagctgc 120
 atccgctgta gaggggtggat aaaatcctgc aggaaagatg gcatctggaa tgtcagcggg 180
 agccaccgac ctctgaggat gcaccccgca ggtgtgatgc ggggccagtt ccaaggctgg 240
 gttaggtttt accctggctt ctgtgttgta ctctcattct cttcctcttt cttctaatac 300
 ctgctctggg aggcacagc ccatgtccag tgtgcaggcc atggagacc acacggcaag 360
 20 gaactggaac cccctgccag cagcctcggg ggtccagtcc ttagatgggt ccctgtgggtc 420
 agcaatgcac ctgtgacctc cgggctatgt ctctgtggtag ttgcttttgt gttttaacat 480
 agcaacagga aactagccta ttaccacca atcccattcc aggctgcttt caaacgcagc 540
 tcaggctaga acaccagcac ggggacacag ctgagacttg gggtttgcga cgggaacacg 600
 cccatgctgt gcctctgaat ctggcaccgt caccctgtgg cctgggttca gcaacttggc 660
 ctcaccttcc ttgtctgtga aattcagact gggctcctgt gagatgattg gagagaatgt 720
 25 atgaactatg tgagaacgcc acctttgtgc gtatctcacg cagtgtcttc cctccttcc 780
 aaagtcttct gctgtctcta gacacaccg acgtgggggg ggggggttcc ctgggtctcc 840
 tcctaggtct gtcccaggag ggcacgact gaaggccgag agaatcccgg gggctgcatt 900
 gcgcccgcgc aaggactcca cacaggacct ttcattttcc caactgtgct gagccagcgg 960
 gccggcagag agcaggtggc tgacaggccc cggggagccg gaccgcctgg gtctaattct 1020
 cccgcagact cccttctgtg gcgctttggg gcttgggct cagtttctc aaaaggaatg 1080
 30 aggggctttt ttggaacggt aaataatttc ctacgtggtt gcgggtaggg agaaggagaa 1140
 agagaggagc gcgcctgcmc gcctggaatc gtgcccgat cagagcaagc gctctaaaag 1200
 tgttacaac ataaaggcgc caactaaaa acccgtagtg agcgcaggca gaaaccacgg 1260
 gtaagagaag tggagaagct tcgcgtaggc cccagggtcc cgagccccga gtctcgagcg 1320
 cagaatcag ggtgccaatg ctctcctccg cgcctccagc cgtctgcctt ggccatgcgg 1380
 gccgccccac cgggatgagg gcgctcaggc cggacgctgg ggccccgggt tctcgccccg 1440
 35 cccccccctc ggggattcag aggggcccggg aggagcctcg cgcattgtgca cagctggcgc 1500
 cccccgcccc ccgcgcacag ctgggacgtg ggcccgggcc gggcgggccc agtcgggagc 1560
 cggccgtggt ggctccgtgc gtccgagcgt ccgtccgcgc cgtcggccat ggccaagcgc 1620
 tccaggggccc ccgggcgccc ctgcctgttg gcgctcgtgc tgttctgcgc ctgggggagc 1680
 ctggccgtgg tggcccagaa gccgggcccga ggggtgtccga gccgctgcct gtgcttcccg 1740
 accaccgtgc gctgcatgca tctgctgctg gaggccgtgc ccgcccgtggc gccgcagacc 1800
 40 tccatcctgt gactgcccgc ggggacgccc gggcgccggg gtccggggct tctgtggagat 1860
 ccgggagcgc aggggtgatc ggaggtgggg ggcgcggagg gtggaggggg catcggggcg 1920
 gcggggggccc tggggacttg ggacgcagaa gggaaacctc gaagggggac gtggggggac 1980
 ctgggcgccc ggacccgctg ggcccttgggt cgcctgcgg gagacgccga gggcggaac 2040
 agagcgtgt gcgcccggcc ttcgtagccc cctttgttcg gaactcggaa tccccgagg 2100
 actgggaagt tgttgagacc tccggggctc cccccgctcg cctcccgcgc ccccctctca 2160
 45 tgctccgccc gcctcccgtt tccccctggt tcgcccggcc tctcctgcct accttcccc 2220
 cgctcaggac ccctcggctc ccctccgctc cccgagcggc gcgcagcccc ctccgtcctc 2280
 ccagccccct ccgccccgtt cctcgtcctg tctcctccc tctcctcctc ctcttctctc 2340
 tccccctctt cctcctctc ccttctctc tctcctccc cttcctctc ctctcctctt 2400
 cccctctctc tccccctctt ccttctctc ccccagctc cgccctctcc cctcccccg 2460
 50 ccccttgag cgcagtgccc accccatccc cccgcccgg 2500

<210> 11
 <211> 2200
 <212> DNA
 <213> Homo sapiens

<400> 11

EP 2 272 975 B1

5 cctcgccccc tccagccggc cccccgggccc cctcctctcg gcgcccggac cttggccctc 60
 cctctccttt cccactttct tctttgccct aacttggccc ccattccccg ctcatttctt 120
 ctgcgacccg ggctcgccaa tccctctttc caagtccctc ttccagcccg gccttctctt 180
 cgggttcgcc ccccttctcc ccaatctccg tcctcttccc tcccttcgcc ctccccctt 240
 tcttctctct tcccctcacc caaccctggt tcccctogtt cctcagtcce gatctctccc 300
 ttactctgtc cccgccact ctgcgcccggc ctctcagtc ccagtggtgg 360

10 acggccgcgc cccactgac agccgcccgc cgccggccc ccccgcgcc cgccgggccc 420
 ctaaaacccc cgcgcccgc cctccaccgc cgcattctt ccagcgccca gcctcccgcc 480
 ctctctcttg ctggccgcac gccccggccc cgcgcacct cgcccggctc cgcagccgct 540
 acccgcgctt cgttgccctg tgggactccg agcagagccc gagggaacct tcctcttctt 600
 ctggggggcga cttttgtttg cttgcctggt tctttctggt gacttttgca gctttccaat 660
 atccgtcttc ggagcgcacg ggaatccgcc gagctctgcy tgcagccct ttttctttt 720
 gaggttcaca tttttgaaa ttttacgcca gggctttgt aatttctcc cccgccgct 780
 15 gacggctctg gagtcgctcg gggctttagg ccggttatgc aacgtgtacc gctcggggct 840
 gccggctgca cctccgccgc gcctcgccc tcactgcyct agaccggcg ccccgcgtct 900
 cgcttcgcyg gcagtcaggg ggcccggcgt ctgctcaggt ctccagctag agcagggagc 960
 ccgagcccca gggagtcacc ggagccgacg aagggttat tagaccctga ctctttctg 1020
 aggcgcgcag atttgtctt tgatcactcc ctctccgcyg gtctacggcc gcgcgcttc 1080
 ggcgcccggc atggggagaa gacggaggct gtgtctccag ctctacttc tgtggtggg 1140
 20 ctgtgtggtg ctctgggcyg agggcacggc cggccagcct cagcctctc cgcccaagc 1200
 gccccggccc cagccgccgc cgcaacaggt tcggtccgct acagcaggct ctgaaggcgg 1260
 gtttctagcy cccgagtatc gcgaggaggg tgccgcagtg gccagccgcy tccgccggc 1320
 aggacagcag gacgtgctcc gagggtaagt gggcaagcgy ctccgcacct agggctccg 1380
 cttgggggag gggggaatcc tcagtttggc ggccttctgy cccactccgt cccagacct 1440
 ttagctggag cctagagctg cagccccctt tgccagaata tccaaagacc cccaggagcy 1500
 25 cgteccccct ttccttccca accccgcagc tcagcgggcy gaaagccctc tctccgggg 1560
 ttgggcygcy ggtggttagg gggctccagg gtgcccagtc cagagcgtgt gcagagctcy 1620
 cgctgcggga acaggtctg aatgtccgcy ggcagccggc cctgggtccg cctgctgcy 1680
 gggccagaga agcctgctt ctccccacgt cggggccgcy gctcgtgagc cttttgtttg 1740
 aggacgtgtg cagggttcac agctcacct ctcatcgtca acccgagcgc tccacctgc 1800
 gacgcgctt ccttgacacg tcggggccaa agtaacagtt gaccaaggag gaatggatt 1860
 30 ggggaaggag gcaaggattc tttggaacgy aatggctcct ttgttctctg catctggaag 1920
 ctagaatagt agcaaattat atgtttccat gcctctttc gccctttaa aaggcaggca 1980
 agggacgaca gatgaaagc agtgtttaga ctttctgac cctcctgcat tccagcatc 2040
 agctcttttg cttccacgcy tgccctccga tctccaataa tttgaagtgt aattttgatt 2100
 tgtttgtgt cctgaaatct actcgtcgy ggcattgctt acgaagacc tttatatgtt 2160
 gctgcatccc tctacctatc tgttacgtga ccgcycttgt 2200

35 <210> 12
 <211> 2000
 <212> DNA
 <213> Homo sapiens

40 <400> 12

45

50

55

EP 2 272 975 B1

	ttggaagaaa	aggatctccg	aggaaggggc	tgagagaagg	gcagggtgaa	ctggactaaa	60
	ggccagagta	ggaaggagaa	gaggggccaa	aaaagaaggg	gatgaaatta	agcacagaag	120
	atgggtaaag	aaaaaagtat	cagggaaagg	gcaaaataag	agaaagcctt	gaggataaga	180
5	gggtagaagg	ctaaagaaca	aggggaccac	tgggtcgggg	aagcgctgcc	tgaacggcgg	240
	gacagtgaca	aagaaagggc	gctggcgata	ttcgcaccaa	gggtgcgaaa	cgcaatcggg	300
	aggtgagaaa	tggaaaagaa	gcgaatgcc	ggctacaagt	agcctgggac	tgaaagggga	360
	cctgggggag	gggctgggcc	cagggcagaa	aagtccaggt	tcccatgcbg	cctgggcca	420
	cgtggagcgg	gcbctgaatc	accgttcagc	cgccccctc	ccctcctccc	cgaccgggtc	480
	ccgcagtc	cgctcctcg	gccgcccct	ccacggggcg	gggcccctgg	ccgggaccag	540
	cgcccgggct	ataaatgggc	tgcbggcag	ccggcagaac	gctgtgacag	ccacacgccc	600
10	caaggcctcc	aagatgagct	acacgttgg	ctcgtgggc	aaccggtccg	cctaccggcg	660
	ggtaaccgag	accgctcga	gcttcagccg	cgtcagcggc	tccccgtcca	gtggcttccg	720
	ctcgcagtcg	tggctcccg	gctcggccag	caccgtgtcc	tcctcctata	agcgcagcat	780
	gctcggcccc	cgctcgtct	acagctcggc	catgctcagc	tccgcccaga	gcagccttga	840
	cttcagccag	tcctcgtccc	tgctcaacgg	cggctccgga	cccggcggcg	actacaagct	900
	gtcccgcctc	aacgagaagg	agcagctgca	ggggctgaac	gaccgctttg	ccggctacat	960
15	agagaagggtg	cactacctgg	agcagcagaa	taaggagatt	gaggcggaga	tccagggcct	1020
	gcggcagaag	caggcctcgc	acgcccagct	gggcbgacgc	tacgaccagg	agatccgcga	1080
	gctgcgcgcc	accctggaga	tggtgaacca	cgagaaggct	caggtgcagc	tggactcggg	1140
	ccacctggag	gaagacatcc	accggtcaa	ggagcgttt	gaggaggagg	cgcggttgcg	1200
	cgacgacact	gaggcggcca	tccgcgcgct	gcbgaaagac	atcgaggagg	cgctcgtggg	1260
20	caaggtggag	ctggacaaga	aggtgcagtc	gctcaggat	gaggtggcct	tcctgcggag	1320
	caaccaagag	gaggagggtg	ccgacctct	ggcccagatc	caggcatcgc	acatcacggt	1380
	ggagcgcgaaa	gactacctga	agacagacat	ctcgcgcbg	ctgaaggaaa	tccgctccca	1440
	gctcgaagc	cactcagacc	agaatatgca	ccagggcga	gagtggttca	aatgccgcta	1500
	cgccaagctc	accgagggcg	ccgagcagaa	caaggaggcc	atccgctccg	ccaaggaaga	1560
	gatcggccgag	taccggcgcc	agctgcagtc	caagagcatc	gagctagagt	cggtgcggcg	1620
	caccaaggag	tccctggagc	ggcagctcag	cgacatcgag	gagcgcaca	accacgacct	1680
25	cagcagctac	caggtaggaa	ccgcbgctgc	gcbggccagcc	tgcgcbgcbg	ccagcggcgc	1740
	gcgccccga	cacttgggct	cgtgcccag	cgccctctcc	gccgcbgctc	ctggtggcgc	1800
	ctcgcctagag	cagcgcgccc	gcagacctag	ggtatttgcg	gatcagcbg	ctcgcctatc	1860
30	tcctcctcca	cactcgcgcc	ccaccacct	gccccagctg	ctaagggtct	tgacctttt	1920
	cagaaacgtg	catcttttcc	agttctaatt	ttgcagcctt	gcaggtttaa	agcaggaggg	1980
	atgaattcgg	tagtgataa					2000

<210> 13
 <211> 2300
 <212> DNA
 <213> Homo sapiens

<400> 13

EP 2 272 975 B1

5
 10
 15
 20
 25
 30

```

tcagattgtc attgggaggg tgaataaatg aatgcttgca ttatgagagt ttgggggagc 60
aaatatgccca cagactctta tctgaagcca tcagatttag tggctgcgaa cccaccgaag 120
tcagggattt acatttttta cagcaacgag agaaaacttc ccctttcctc tgcagaagtc 180
aggactggat ctcaaaaata gaaatgtgtc ctctaaatg tgtgcccac cccgtgggtg 240
acaacaacag gatttcccaa gatagctgcc acacacttgg tttctaactc ctgtattgct 300
tccccgccag aatgtcgaag tccttcccga atatgccag tcatactttc tgaacttttg 360
agcaaacacc gtccggcttc ttgtgctttc ctcaaagacc ccaggcaccg gcagggagga 420
cacaggcccg ggcagagcgc ccctgcgcgg gggattcctg ccaactccg cccagcctgcg 480
gcgcaaacgc tcttctcagc cgcagtccca cccgctgctg gcaatctgaa tgaggagccg 540
cgctattttt acctccccgg ctgcaatcct ttatatttac atgcaggaag caaatatata 600
agggattaag aaggagatgc gtggccttag tttatccaga gcaggaagag gttggaatag 660
gagaggggat gtgaagtctg ggggtgggga aaaggcaggt ggacttcggc tggttgtttt 720
ctcccgatca tccctgtctc tggcctggaa acccccgta cctctttctt ctggcttacc 780
cgtgactgcc ggctccccct ccaccgcccc catcttttga ggtaccacc gtcacctccg 840
atgctgcttg ggtgctgca tcaactctgt cgtttacccc ctccccgccc ccccaacaaa 900
gcatgcgcag tgcgttccgg gccaggcaac agcagcagca cagcatccag caacagcacc 960
agcaccgcaa gccccgctcg ggcgcgctct cggggggcgg ggcgcacgcc cgctccgcgc 1020
gtccccgcgc cgctcgctcc cgcgcgtccc cgcgcgcctc gctcccgcgc gccgcctcag 1080
catcctcagg cccggcggca gccccgcgag tcgtgaaagc ggccgcgccc gccgggggag 1140
ggagtgcgag ctggggaggg tccaagttag cggagcggcg aggaccctg gactcctctg 1200
cgtcccgcgc cgggagtgcc tgcgaggcta ggcgagccgg gaaagggggc gccgccagc 1260
cccagagccc gcgccccgtg ccccagccc ggagccccct gcccgccgcg gcaccatgag 1320
cgccgagccg gcgtgaccgg ctccgcccgc ggccgccccg cagctagccc ggcgctctcg 1380
ccggccacac ggagcggcgc ccgggagcta tgagccatga agccgcccgg cagcagctcg 1440
cggcagccgc ccctggcggg ctgcagcctt gccggcgtt cctgcggccc ccaacgcggc 1500
cccgcggctc cgggtgcctgc cagcgcggcg gccgcacgc cccctgccc gctgcttctc 1560
gtccttctcc tgetgcctcc gctgcggccc tcgtcccggc cccgcgctg gggggctgct 1620
gcgcccagcg gtgggtatgg ccccgctgccc tttgcgttgg ctttcccgcg gggccctgca 1680
gaggaaagcg aagggcgcgc gggctcctgt gctccgggct tgtcccggc tcggccttcc 1740
cttccctccc tgctgtctt tccacccttc tcgttcccaa acccccattc atcccagttc 1800
acttttgaa gtccatttct gttgcattcg cgaaaaacc attccaattc ttgttggttc 1860
cactgggagc tgtttagtgg atcctgggtc cctcagcag ctctgtgcaa cttgcggagg 1920
ggcaaccagt ggatgggaaa tacagcgagg gagcaagttg ctacttgcgt ggtggaacct 1980
taatgtgaat gcggggagga tgtagtata atagtggtaa tgggctgttt cctcaaattt 2040
cgtatccggc gcattcagtg cggttggaat taaggtgggg gaggcacact tcggggacca 2100
aagaattaag gtgctgaaga catacttcat gcacgacctt tggttctgat ttctcaaagt 2160
gcttgtcatt ataataataa taccatcttc tataattga tgattggaag 2220
tactgaaag cagaaagctg gctttgtcag gaaaaataaaa agaaattggg aagctgccag 2280
catctgtatc cctacatggc 2300
    
```

35 <210> 14
 <211> 3000
 <212> DNA
 <213> Homo sapiens

40 <400> 14

45
 50

```

tactgccgac tttaggcttc tctggatctc agggccccct ctctaagatg catcctagag 60
gaccaaaaaat acacttttatt tgggcttcgc ctgcttttgt ggaagggtag ttactagag 120
gatataatct cgtgttttaa tttgctctct ctctaaagg aaatgtggag aaaaaaaaaa 180
agcagaaatt ggaaataacc aatatttagt ttatttcatt cgattcttag gggaactggg 240
gaggagccta agatgatttt cccttcctag agaaagaatc caaagtccag ggaaatagcg 300
acaggggagt tcaagactgc ccctgctagt ccttccctgg ctactctccg ctgcgatcgc 360
aggatagctc tcattagcag gagaatcggg caagtgtgtg gataagtaga gagtgtgttg 420
aacaacttgt aacgttttat gaaatagca ttgtcatggt tccctaaaag gctttgcgga 480
agccgtttgt ctttactaat caagtcttta cttacacaaa agtagaagta gaagtgttt 540
tagaaaacat actaacaatc ttctatcccc ttgaagacca gagtagcaga aaacaggtga 600
tttgcattat aaaattgcac tcactttttc ctctttcag atttcacatt acattagccc 660
    
```

55

EP 2 272 975 B1

atttgtgtta cgggtgtataa aaaatggaac aggcgcctcc actgcattgt tctcctttaa 720
 aatagatca cttacaccct aactttgttt tccttaaatt cgattcttaa caggagagct 780
 ttctattatt tcagatggag tgaggttgca cgactgggat ggaagaaagg aatccctaa 840
 atttggggga atttctgttc tctgttccaa gaccatttta ctgggggtgt ggggggtggc 900
 5 cggcggtca gggcagtga acgcagtcgc ggctgcgcca tccctgcaact tccaggcgcg 960
 cgggagggac cggcggggac gcgagctgcg gactctggcg aactcggggg aggcagacag 1020
 ggggagggcgg acaccagcc ggcagggcgc tcagcctccc cgcagccggc gggcttttct 1080
 cctgacagct ccaggaaagg cagaccctt cccagccag ccaggtaagg taaagactgc 1140
 tgttgagctt gctgttactg agggcgcaaca gaccctgggg agaccgaagc ttgccactgc 1200
 gggattctgt ggggtaacct ggtctacgg aagtttctg aaagagggga gaagggttg 1260
 10 catttttccct atggaggatt cttctctctc tagcatttcg tttgatgtat tcaactggta 1320
 gaagtgagat ttcaacaggt agcagagagc gctcacgtgg aggaggttg gggcgcccg 1380
 ggcaccacc caccctcct cgggaccgcg cctatttcta aagtacacg tcgacgaact 1440
 aacctatgct ttaaattcct cttccagcc ccgtgagtc gcggcgacat tgggctgg 1500
 ggtggctggg aacgggtccc tcctccggaa aaaccagaga acggcttggga gagctgaaac 1560
 15 gagcgtccgc gagcaggtec gtgcagaacc ggcttcagg accgctgagc tccgtagggc 1620
 gtccttgggg gacgccaggt cgcggctcc tctgccctcg ttgagatgga caacgcctcg 1680
 ttctcggagc cctggcccgc caacgcacgc ggcccggacc cggcgtgag ctgctcaac 1740
 gcgtcgactc tggcgccgct gccggcgccg ctggcgggtg ctgtaccagt tgtctacgcg 1800
 gtgactctgc cgtgggtct gccgggcaac tccgcccgtg tgtacgtgtt gctgcccggc 1860
 ccccgatga agaccgtcac caacctgttc atcctcaacc tggccatcgc cgacgagctc 1920
 20 ttacgctgg tgctgcccac caacatcgcc gacttctgc tgcggcagtg gcccttcggg 1980
 gagctcatgt gcaagctcat cgtggctatc gaccagtaca acacctctc cagcctctac 2040
 ttctcaccg tcatgagcgc cgaccgctac ctggtgggtg tggccactgc ggagtcgagc 2100
 cgggtggccg gccgcacct caagcgcgcg cgcgcgggtg gcctggccgt gtgggggatc 2160
 gtcacactgc tcgtgctgcc cttcgcagtc ttcgcccggc tagacgacga gcagggcccg 2220
 cgccagtgcg tgctagtctt tccgcagccc gaggccttct ggtggcgcgc gagccgctc 2280
 25 tacacgctcg tgetgggctt cgccatcccc gtgtccacca tctgtgtcct ctataccacc 2340
 ctgctgtgcc ggctgcatgc catgcccgtg gacagccacg ccaaggccct ggagcgcgcc 2400
 aagaagcggg tgaccttct ggtgggtggca atcctggcgg tgtgcctcct ctgctggagc 2460
 ccctaccacc tgagcaccgt ggtggcgcgc accaccgacc tcccgcagac gccgctggc 2520
 atcgctatct cctacttcat caccagcctg agctacgcca acagctgct caacccttc 2580
 ctctacgct tcctggacgc cagcttccgc aggaacctcc gccagctgat aacttgccgc 2640
 gggcagcct gactcccca gcgtccggct ccgcaactgc ccgccaactc tggccagcga 2700
 30 gggaggagcc ggcgccagag tgcgggacca gacaggccgc ctaggcctcc tggggaacc 2760
 gactcgcgcc ccatacccga cctagcagat cgggaagcgt gcgactgtgc ccgcaggtg 2820
 acctgccaa gccctccagg tgatgcgcgg ccatgccggg tgaggagaac tgaggctgag 2880
 atcgccacac tgagggtcc ctaaagccga ggtggaggaa gaggagggtg gaggaggag 2940
 ggggtattgc tgggaaccgc cccctcctg ccctgctccc tgctgcccc cccgagccct 3000

35 <210> 15
 <211> 3000
 <212> DNA
 <213> Homo sapiens

40 <400> 15

45

50

55

EP 2 272 975 B1

5
10
15
20

```

gaatacatta aagtaggggc aacccttgag cccagacttc tgccatgtga agaccctttg 60
aaaatcctga caaacacagg tactgcgtaa gtggtcagct aattaaagag gggaggtgga 120
gctgtccttt gtgtatccaa taagtaccca ttatctcatt tgagcatgaa aagaggccac 180
tgttattact ttcaagaagg aaagtaagca ggatagctca tattttttaga accattcctc 240
accaaaatgga ataattccgg tgaaaagtgg agtgaggaa gaaagaaaaa aaaaacttct 300
aatcataatg tttgggaata agaaaggaag aagaaactca cgtcaaagcc gactttctcc 360
tgcagctgta aaataaactc ttaagaccct tcctgctgaa actctggaga ggaaaactgg 420
agtggcgggt gggctttgcc tgcagctcaa ctctccctcg cggcgcgggc gcggctgggt 480
tcagcacctc ggaaagcgcc cctcgcggcg ccccgggatt acgcatgctc cttggggccc 540
gccgccttgg ccgtgcaagt gccaccgtaa ctggtgagag ccgctggcaa cccaccgga 600
gttgacaacc gcggagagag gcagacaccc actgacctcc aggaagctga gcgtggtgga 660
tggaaactcta cgatctcttt ctctccaagg acggaaacct catccaagca gtcccagagg 720
aaacggataa aggtatattga aagggagcga gcggcccaa atcgacaat tgagcggctg 780
ggggagtatt gcgccagtgc cccagtgacc gcgggacacg gagaggggaa gtctgcgttg 840
tacataagga cctagggact ccgagcttgg cctgagaacc cttggacgcc gactgcttgc 900
cttacgggct gcactcctca actctgetcc aaagcagccg ctgagctcaa ctcctgcgtc 960
cagggcgctc gctgcgcgcc aggacgcgct tagtaccag ttcttgggct ctctcttcag 1020
tagctgcttt gaaagctccc acgcacgtcc cgcaggctag cctggcaaca aaactggggt 1080
aaaccgtggt atcttaggtc ttgtccccc gaacatgacc tagaggtacc tgcgcatgca 1140
gatggccgat gcagccacga tagccaccat gaataaggca gcaggggggg acaagctagc 1200
agaactcttc agtctggtcc cggaccttct ggaggcggcc aacacgagtg gtaaccgctc 1260
gctgcagctt ccggacttgt ggtgggagct ggggctggag ttgccggacg gcgcgcgcc 1320

```

25
30
35
40
45

```

aggacatccc ccgggcagcg gcggggcaga gagcgcggac acagagggcc gggtgcggt 1380
tctcatcagc gtggtgtact ggggtggtgt gcgcctgggg ttggcgggca acctgctggt 1440
tctctacctg atgaagagca tgcaaggctg cgcgaagtcc tctatcaacc tcttcgtcac 1500
caacctggcg ctgacggact ttcagtttgt gctcaccctg cccttctggg cggtgaggaa 1560
cgctcttgac ttcaaatggc ccttcggcaa ggccatgtgt aagatcgtgt ccatggtgac 1620
gtccatgaac atgtacgcca gcgtgttctt cctcactgcc atgagtgtga cgcgctacca 1680
ttcggtggcc tcggctctga agagccaccg gaccggagga cacggccggg gcgactgctg 1740
cggccgggac ctgggggaca gctgctgctt ctcggccaag gcgctgtgtg tgtggatctg 1800
ggctttggcc cgcgtggcct cgctgcccag tgccatttcc tccaccacgg tcaaggtgat 1860
gggcgaggag ctgtgcctgg tgcgtttccc ggacaagtgt ctgggcccgc acaggcagtt 1920
ctggctgggc ctctaccact cgcagaaggt gctgctgggc ttcgtgctgc cgctgggcat 1980
cattatcttg tgctacctgc tgctggtgcg cttcatcgcc gaccgccgcg cggcggggac 2040
caaaggaggg gccgcggtag ccggaggacg cccgaccgga gccagcggcc ggagactgtc 2100
gaaggtcacc aatcagtgga ccatcgttgt cctgtccttc ttctgtgtt ggctgcccaa 2160
ccaggcgctc accacctgga gcacctcat caagttcaac gcggtgccct tcagccagga 2220
gtatttctctg tgccaggtat acgcgttccc tgtgagcgtg tgcctagcgc actccaacag 2280
ctgcctcaac cccgtcctct actgcctcgt gcgcgcgag ttccgcaagg cgctcaagag 2340
cctgctgtgg cgcacgcgct ctccctcgat caccagcatg cgccccctca ccgccaacta 2400
caagccggag cacgaggatc aggggctgca ggccccggcg ccgccccacg cggccgcgga 2460
gccggacctg ctctactacc cacctggcgt cgtggtctac agcggggggc gctacgacct 2520
gctgcccagc agctctgcct actgacgcag gcctcaggcc cagggcgcgc cgtcggggca 2580
aggtggcctt ccccgggagg taaagaggtg aaaggatgaa ggagggctgg ggggggcccc 2640
atttaagaag taggtgggag gaggatgggc agagcatgga ggaggagcct gtggataggc 2700
cgaggacctt ctctggagag gagatgcttc gaaatcaggt ggagagagga aattggcaaa 2760
gggatagaga cgagccccac gggccagaca cccaacctcc gctccgcacc ccacagcctc 2820
tccttactct tcccacgctg agtagtgtgg gggcgcggcag aagcgaagac aagcagcaaa 2880
aatgtagaga aattggcacg gggagcgggg cttagccaaa tgatgcacag acaattgtgc 2940
ccgtttattc cagcgaactc tgcggagagg gcaagccgctc gcacaaacac tcctttgcgt 3000

```

<210> 16
<211> 2200
<212> DNA
<213> Homo sapiens

<400> 16

EP 2 272 975 B1

```

gtccccgat tccctcacc atcatataac gtgtgtattt attatgtttc ccgtttcctc 60
tgtctccgcc agcagaatgt aaactccatg aggtcaggaa tctccgagtt atgttgcgcc 120
agtgtaatcc aagagcccgg aacagtgcct ggcacacagc gggcatatgg aagaacaaat 180
gtgtgaaggt gtgaatgaat gaataattga aagaataaat agtagttctc agcctcacag 240
aacacgggtc acaacctcaa atgacctgct accctgcccc taaataacag agatgcagga 300
gtaagtgtct ggctgtgacc tgtcaacatg ctaagccgct caaacaaaac tgcccaacag 360
cccgctggcc gcctatattg agcactgggc cctgagccgc acattcccat ttcgttgata 420
aagaaactga ccagatagtt taagtggcct gctgcggaag acagagctgg tgctgcaccg 480
gtcgtgtctt ccccagtcct tttttggcct cctttctgac gcgacgcaga ccccagttct 540
ggagagtctg tcactcgctc cccgtggtgg gagatcagag gcctggtgtc cttgggagcg 600
gcgagcgggt ctcggcgagc gatagaaagg gagtgcgagc ccgagtcccc cagatccctg 660
ggaaccgcgc ccaccctccc gccctgccc atccccggc gcgctgtcag tctccattag 720
cgtaacaggg ctccagacgg agcggggccg gcgctggggt aatgcaatcg gcgcttacc 780
tggggcgcag gctacattac cagcccggcc cccgccaggc acggccagaa ccagtcagcc 840
cgcgccctgc cggccgcccc gcgctccag ctcttcccc gccccgccc aacgccacac 900
ggcggagccc agccccagcc cgcgcccag agcctgccc ggccgcccg gtcggggccc 960
ggcagggcgc aaggcaccag ggatcccctc gccgccggac acgtgagtgc gccctgagcg 1020
cgggacaggg ctaggtctgc ctgggaggcc cgggccgaga cgcgccagca gagggctagc 1080
gagttttagt tgcagtgcag ttaagtgtcc gagaaggctc ctgtggctgt tgaagtgtcg 1140
cggacctgag ctggggaggg ggtcggcacg ctgccctcag cctcggtagg ttcaatcca 1200
gccatttggg gcaggcgaga gtgggtgaac gaggaaaagt gctgcagggg cttcagcccg 1260
ccccagaggg ctgtcagaag tctccaactc ttgagttccg gcgtgcccc aacctgtgtt 1320
ccaaatttt ccagcggacg cgcgctcttt tctgggaacc ctgcgtccgc tcagcgcgcg 1380
ctcatcccag tgtctaaggc gctcccgggt ggtcttggga gttgcaagta gggaggaacg 1440
gccgggtaac cacctctttt ccttttatcc aagcagagcc tcggcgtgcc cccaggaccg 1500
gtaaagtctc tctcgccagc cgcattccatg ctctgggcgc ggatgaacc gcaggtgcag 1560
cccgagaaca acggggcgga cacgggtcca gagcagcccc ttcgggcccg caaaactgcg 1620
gagctgctgg tgggtgaagga gcgcaacggc gtccagtgcc tgctggcgcc ccgcgacggc 1680
gacgcgcagc cccgggagac ctggggcaag aagatcgact tcctgctgtc cgtagtcggc 1740
ttcgcagtgg acctggccaa cgtgtggcgc ttcccctacc tctgctaaa gaacggcggc 1800
ggtgagcgtg gggtcgggct gggaaattga atctgggagg tccactgtct gcagcgggtg 1860
ctgggacagg agctggaata cacacggaag gtaggcgagg agacaggggc aaatctgggg 1920
cgcagaaaga actggacagg gctaacggga aaaaaaaaaag attggagtcc tctggaaggt 1980

cattttccca ggctctttgc agagtacctc gagctcattc cagcggaaagt gtcaggattg 2040
ggcaccctgg aagcaaaaaca gcagaagagt gaaatcgagt catgacccta aagtcatggg 2100
aggggtatgg atggaaagga cagaatctgg ggtgccaggt tgggtggggg agcctgacct 2160
tttgatggtc tgctggaagg gaggtggaga ttccaagagc 2200

```

35 <210> 17
 <211> 98
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <221> modified_base
 <222> 20,23,31,46,51,53,55
 <223> Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176), n=m5c

45 <400> 17

```

gttggccact gcggagtcgn gcnggggtggc nggccgcacc tacagngccg ngngngcggg 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

```

50 <210> 18
 <211> 98
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <221> modified_base
 <222> 31, 46, 51, 53, 55
 <223> Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176),n=m5c

EP 2 272 975 B1

<400> 18

gttggccact gcgagtcgc gccgggtggc nggccgcacc tacagngccg ngngngcggt 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

5

<210> 19

<211> 98

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)

<400> 19

15

gttggccact gcgagtcgc gccgggtggc cggccgcacc tacagcgcg cgcgcgcggt 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

20

<210> 20

<211> 14

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Designed oligonucleotide for experiment

<400> 20

gccacccggc gcga 14

30

<210> 21

<211> 19

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Designed oligonucleotide primer for PCR

<400> 21

gttggccact gcgagtcg 19

40

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Designed oligonucleotide primer for PCR

<400> 22

gcacgacgag tgtgacgatc 20

50

<210> 23

<211> 98

<212> DNA

55

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)

EP 2 272 975 B1

<400> 23

gttggccact gcgagtcgc gccgggtggc cggccgcacc tacagcgccg cgcgcgcggt 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

5

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Designed oligonucleotide primer for PCR

<400> 24

15

ctcagcacc aggcggcc 18

<210> 25

<211> 20

<212> DNA

20

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer for PCR

<400> 25

25

ctggccaaac tggagatcgc 20

<210> 26

<211> 386

30

<212> DNA

<213> Artificial Sequence

<220>

35

<223> Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419 25687390-25687775 Homo sapiens)

<400> 26

40

ctcagcacc aggcgccgc gatcatgagg cgcgagcggc gcgcgggctg ttgcagagtc 60
ttgagcgggt ggcacaccgc gatgtagcgg tcggctgtca tgactaccag catgtaggcc 120
gacgcaaaca tgccgaacac ctgcagggtgc ttcaccacgc ggcacagcca gtcggggccg 180
cggaagcgggt aggtgatgtc ccagcacatt tgcggcagca cctggaagaa tgccacggcc 240
aggtcggcca ggctgaggtg tcggatgaag aggtgcatgc gggacgtctt gcgcgcgctc 300
cggtgcagag ccagcagtac gctgctgttg cccagcacgg ccaccgcgaa agtcaccgcc 360
agcacggcga tctccagttt ggccag 386

45

<210> 27

<211> 386

<212> DNA

50

<213> Artificial Sequence

<220>

<221> modified_base

55

<222> 14,18,20,31,33,38,40,42,44,66,78,80,88,92,120,123,134,160,173,179,181,187,20 3,237,245,262,280,285,292,294,297,301,320,338,346,357,365,368

<223> Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419 25687390-25687775 Homo sapiens), n=m5c

EP 2 272 975 B1

<400> 27

```

5      ctcagcacc  aggnngcngn gatcatgagg nngagnggn gngngggctg ttgcagagtc  60
      ttgagnggg  ggcacacnng gatgtagnng tnggctgtca tgactaccag catgtaggcn  120
      gangcaaaca tcnngaacac ctgcaggtgc ttcaccangn ggcacagcca gtnggggcn  180
      nggaagnggt aggtgatgtc ccagcacatt tngggcagca cctggaagaa tgccanggcc  240
      aggtngggcca ggctgaggtg tnggatgaag aggtgcatgn gggangtctt gngngngtc  300
      nggtgcagag ccagcagtan gctgctgttg cccagcangg ccacngngaa agtcacngcc  360
      agcangngna tctccagttt ggccag  386

```

10

<210> 28

<211> 386

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419 25687390-25687775 Homo sapiens)

20

<400> 28

```

25      ctcagcacc  agggggccgc gatcatgagg cgcgagcggc gcgcgggctg ttgcagagtc  60
      ttgagcgggt ggcacaccgc gatgtagcgg tcggctgtca tgactaccag catgtaggcc  120
      gacgcaaaca tgccgaacac ctgcaggtgc ttcaccacgc ggcacagcca gtcggggccg  180
      cggaagcggg aggtgatgtc ccagcacatt tgcggcagca cctggaagaa tgccacggcc  240
      aggtcggcca ggctgaggtg tcggatgaag aggtgcatgc gggacgtctt gcgcggcgtc  300
      cgggtgcagag ccagcagtac gctgctgttg cccagcacgg ccaccgcgaa agtcaccgcc  360
      agcacggcga tctccagttt ggccag  386

```

30

<210> 29

<211> 30

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 29

```

40      gccaccgca aagtcaccgc cagcacggcg 30

```

<210> 30

<211> 30

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 30

```

50      gccagcagta cgctgctgtt gccagcacg 30

```

<210> 31

<211> 30

<212> DNA

<213> Artificial Sequence

55

EP 2 272 975 B1

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

5 <400> 31
cgggacgtct tgcgggcgt ccggtgcaga 30

<210> 32
<211> 30
10 <212> DNA
<213> Artificial Sequence

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

15 <400> 32
aggctgaggt gtcggatgaa gaggtgcatg 30

20 <210> 33
<211> 30
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

30 <400> 33
acctggaaga atgccacggc caggtcggcc 30

<210> 34
<211> 30
<212> DNA
35 <213> Artificial Sequence

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

40 <400> 34
tagtgatgt cccagcacaat ttgcggcagc 30

<210> 35
45 <211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

50 <400> 35
cggcacagcc agtcggggcc gcggaagcgg 30

55 <210> 36
<211> 30
<212> DNA

EP 2 272 975 B1

<213> Artificial Sequence

<220>

5 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 36

atgccgaaca cctgcaggtg ctcaccacg 30

10 <210> 37

<211> 30

<212> DNA

<213> Artificial Sequence

15 <220>

<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 37

20 atgactacca gcatgtaggc cgacgcaaac 30

<210> 38

<211> 30

<212> DNA

25 <213> Artificial Sequence

<220>

<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

30

<400> 38

tggcacaccg cgatgtagcg gtcggctgtc 30

<210> 39

35 <211> 30

<212> DNA

<213> Artificial Sequence

<220>

40 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 39

45 cgcgcgggct gttgcagagt cttgagcggg 30

<210> 40

<211> 30

<212> DNA

50 <213> Artificial Sequence

<220>

<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

55 <400> 40

caggcggccg cgatcatgag gcgcgagcgg 30

<210> 41

EP 2 272 975 B1

<213> Artificial Sequence

<220>

5 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank
Accession No.AC009800 76606-76726 Homo sapiens)

<400> 45

10 **g**cgccggg**tc** **c**gggcc**gat** **g**cgttgg**cgg** **g**ccaggg**ctc** **c**gaga**acgag** **g**cgtt**gtcca** **60**
tctca**acgag** **g**gcag**aggag** **c**cggc**gacct** **g**gcgt**cccc** **a**agg**acgcc** **t**acgg**agctc** **120**
a **121**

<210> 46

<211> 30

15 <212> DNA

<213> Artificial Sequence

<220>

20 <223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 46

g**cg**tcc**cca** **agg**ac**ccct** **acg**gag**ctca** 30

25 <210> 47

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

30 <223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 47

35 ct**ca**ac**gagg** **gc**ag**aggagc** **cg**gc**gacctg** 30

<210> 48

<211> 30

<212> DNA

40 <213> Artificial Sequence

<220>

45 <223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 48

cg**cc**gg**gtcc** **gg**gcc**gatg** **cg**tt**ggcggg** 30

<210> 49

50 <211> 21

<212> DNA

<213> Artificial Sequence

<220>

55 <223> Designed oligonucleotide primer for PCR

<400> 49

gg**ac**ct**gtgt** **tt**gac**gggta** **t** 21

EP 2 272 975 B1

<210> 50
<211> 21
<212> DNA
<213> Artificial Sequence
5

<220>
<223> Designed oligonucleotide primer for PCR

<400> 50
10 agtacagatc tggcgttctc g 21

<210> 51
<211> 117
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Amplified oligonucleotide consisting of objective DNA domain (Genbank
Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII)
20

<400> 51

25 **ggacctgtgt ttgacgggta taacctaaag ttgcgcaatt tgctgtattg cgaaatccgc 60**
ccggacgata tcactcttga ggcgatgtgc cgtttccgag aacgccagat ctgtact 117

<210> 52
<211> 117
<212> DNA
30 <213> Artificial Sequence

<220>
<221> modified base
<222> 15,34,51,58,61,66,82,91,97,ID3
35 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139
384569-384685 Saccharomyces cerevisiae chromosome VII) n=m5c

<400> 52

40 **ggacctgtgt ttgangggta taacctaaag ttgngcaatt tgctgtattg ngaaatcngc 60**
cnggangata tcactcttga gngcatgtgc ngtttcngag aangccagat ctgtact 117

<210> 53
45 <211> 117
<212> DNA
<213> Artificial Sequence

<220>
50 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank
Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII)

<400> 53

55 **ggacctgtgt ttgacgggta taacctaaag ttgcgcaatt tgctgtattg cgaaatccgc 60**
ccggacgata tcactcttga ggcgatgtgc cgtttccgag aacgccagat ctgtact 117

EP 2 272 975 B1

<210> 54
<211> 21
<212> DNA
<213> Artificial Sequence
5

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA
10

<400> 54
ggacctgtgt ttgacgggta t 21

<210> 55
<211> 25
<212> DNA
<213> Artificial Sequence
15

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA
20

<400> 55
aacactaagt tgcgcaattt gctgt 25
25

<210> 56
<211> 25
<212> DNA
<213> Artificial Sequence
30

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA
35

<400> 56
attgcgaaat cgcgccggac gatat 25
40

<210> 57
<211> 25
<212> DNA
<213> Artificial Sequence
45

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA
50

<400> 57
cactcttgag cgcatgtgcc gtttc 25
55

<210> 58
<211> 244
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

<400> 58

EP 2 272 975 B1

taggaaatac attccgaggg cgcccgacaca aggcctatta ttagagggac ctgtgtttga 60
 cgggtataac actaagttgc gcaatttgct gtattgcaa atccgcccg acgatcac 120

5 tcttgagcgc atgtgccgtt tccgagaacg ccagatctgt actgcatcg cacacgagga 180
 gacacagcgt cacgtgtttt gccatthtgt acgacaaatg aaccgcctgg ccacgcctct 240
 aatc 244

10 <210> 59
 <211> 30
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

20 <400> 59
 aatacattcc gagggcgccc gcacaaggcc 30

<210> 60
 <211> 21
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

30 <400> 60
 gcgatcgac acgaggagac a 21

35 <210> 61
 <211> 30
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 61
 agcgtcacgt gtttgccat tttgtacgac 30

45 <210> 62
 <211> 29
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

55 <400> 62
 aatgaaccg cctggccacg cctctaac 29

Claims

1. A method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA contained in a biological specimen, the objective DNA region having a recognition site of at least one kind of methylation sensitive restriction enzyme, comprising:

(1) First step of mixing a DNA sample comprising a single-stranded DNA (plus strand) containing the objective DNA region and a masking oligonucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of a recognition site for the at least one kind of methylation-sensitive restriction enzyme, thereby obtaining a partially single-stranded DNA in which the recognition site for the methylation-sensitive restriction enzyme forms double strand by complementary base-pairing with the masking oligonucleotide, followed by digesting the DNA sample with the methylation-sensitive restriction enzyme wherein said enzyme digests a recognition site containing unmethylated cytosine and does not digest a recognition site containing methylated cytosine;

(2) Second step of obtaining methylated single-stranded DNA from the DNA sample that has been subjected to the digestion treatment in First step by separating methylated double-stranded DNA contained in the DNA sample into methylated single-stranded DNA, and binding the methylated single-stranded DNA to an immobilized methylated DNA antibody, thereby selecting the single-stranded DNA; and

(3) Third step of amplifying the methylated DNA in the objective DNA region from the selected single-stranded DNA to a detectable level by a polymerase chain reaction (PCR) and quantifying the amount of the amplified DNA.

2. The method of claim 1, wherein the immobilized methylated DNA antibody is a methylcytosine antibody.
3. The method of claim 1 or 2, wherein the biological specimen is blood, a bodily fluid, serum, plasma, a cell lysate, or a tissue lysate from a mammal.
4. The method of any one of claims 1 to 3, wherein the DNA sample derived from the genomic DNA contained in the biological specimen is a DNA sample digested in advance with a restriction enzyme for which a recognition cleavage site is not present in the objective DNA region of the genomic DNA, or a DNA sample purified in advance.
5. The method of any one of claims 1 to 4, wherein the methylation-sensitive restriction enzyme is HhaI.
6. The method of any one of claims 1 to 5, wherein a counter oligonucleotide is added when separating the methylated double-stranded DNA into the methylated single-stranded DNA in Second step.

Patentansprüche

1. Verfahren zum Messen des Gehalts an methylierter DNA in einer Ziel-DNA-Region in einer genomischen DNA, die in einer biologischen Probe enthalten ist, wobei die Ziel-DNA-Region eine Erkennungsstelle für mindestens eine Art eines methylierungssensitiven Restriktionsenzym hat, das umfasst:

(1) einen ersten Schritt des Mischens einer DNA-Probe, die eine einzelsträngige DNA (Plus-Strang) umfasst, die die Ziel-DNA-Region enthält und eines maskierenden Oligonucleotids, das eine Nucleotidsequenz umfasst, die komplementär ist zu einer Nucleotidsequenz einer Erkennungsstelle für die mindestens eine Art eines methylierungssensitiven Restriktionsenzym, wodurch eine teilweise einzelsträngige DNA erhalten wird, in der die Erkennungsstelle für das methylierungssensitive Restriktionsenzym einen Doppelstrang durch komplementäre Basenpaarung mit dem maskierenden Oligonucleotid bildet, gefolgt vom Verdauen der DNA-Probe mit dem methylierungssensitiven Restriktionsenzym, wobei das Enzym eine Erkennungsstelle verdaut, die unmethyliertes Cytosin enthält und keine Erkennungsstelle verdaut, die methyliertes Cytosin enthält;

(2) einen zweiten Schritt des Erhaltens von methylierter einzelsträngiger DNA von der DNA-Probe, die der Verdau-Behandlung im ersten Schritt ausgesetzt war, durch das Auftrennen methylierter doppelsträngiger DNA, die in der DNA-Probe enthalten ist, in methylierte einzelsträngige DNA und das Binden der methylierten einzelsträngigen DNA an einen immobilisierten Antikörper gegen methylierte DNA, wodurch die einzelsträngige DNA selektiert wird; und

(3) einen dritten Schritt des Amplifizierens der methylierten DNA in der Ziel-DNA-Region aus der selektierten einzelsträngigen DNA auf einen nachweisbaren Wert durch eine Polymerasekettenreaktion (PCR) und das Quantifizieren der Menge an amplifizierter DNA.

EP 2 272 975 B1

2. Verfahren nach Anspruch 1, wobei der immobilisierte Antikörper gegen methylierte DNA ein Methylcytosin-Antikörper ist.
3. Verfahren nach Anspruch 1 oder 2, wobei die biologische Probe Blut, eine Körperflüssigkeit, Serum, Plasma, ein Zelllysat oder ein Gewebelysat von einem Säuger ist.
4. Verfahren nach einem der Ansprüche 1 bis 3, wobei die DNA-Probe, die von der genomischen DNA stammt, die in der biologischen Probe enthalten ist, eine DNA-Probe ist, die vorab mit einem Restriktionsenzym verdaut wurde, dessen Erkennungsschnittstelle in der Ziel-DNA-Region der genomischen DNA nicht vorhanden ist, oder eine DNA-Probe ist, die vorab aufgereinigt wurde.
5. Verfahren nach einem der Ansprüche 1 bis 4, wobei das methylierungssensitive Restriktionsenzym HhaI ist.
6. Verfahren nach einem der Ansprüche 1 bis 5, wobei ein Gegen-Oligonucleotid im zweiten Schritt zugegeben wird, wenn die methylierte doppelsträngige DNA in die methylierte einzelsträngige DNA aufgetrennt wird.

Revendications

1. Procédé pour mesurer la teneur en ADN méthylé dans une région d'ADN cible dans un ADN génomique contenu dans un échantillon biologique, la région d'ADN cible comportant un site de reconnaissance d'au moins un type d'enzyme de restriction sensible à la méthylation, comprenant :
 - (1) une première étape de mélange d'un échantillon d'ADN comprenant un ADN simple brin (brin positif) contenant la région d'ADN cible et d'un oligonucléotide de masquage comprenant une séquence de nucléotides complémentaire à une séquence de nucléotides d'un site de reconnaissance pour le au moins un type d'enzyme de restriction sensible à la méthylation, en obtenant ainsi un ADN partiellement simple brin dans lequel le site de reconnaissance pour l'enzyme de restriction sensible à la méthylation forme un double brin par un appariement de bases complémentaires avec l'oligonucléotide de masquage, suivi d'une digestion de l'échantillon d'ADN avec l'enzyme de restriction sensible à la méthylation, où ladite enzyme digère un site de reconnaissance contenant une cytosine non méthylée et ne digère pas un site de reconnaissance contenant une cytosine méthylée ;
 - (2) une deuxième étape d'obtention d'un ADN simple brin méthylé à partir de l'échantillon d'ADN qui a été soumis au traitement de digestion au cours de la première étape en séparant l'ADN double brin méthylé contenu dans l'échantillon d'ADN en ADN simple brin méthylé, et de liaison de l'ADN simple brin méthylé à un anticorps anti-ADN méthylé immobilisé, en sélectionnant ainsi l'ADN simple brin ; et
 - (3) une troisième étape d'amplification de l'ADN méthylé dans la région d'ADN cible à partir de l'ADN simple brin sélectionné à un niveau détectable par une réaction en chaîne par polymérase (PCR), et de quantification de la quantité de l'ADN amplifié.
2. Procédé selon la revendication 1, dans lequel l'anticorps anti-ADN méthylé immobilisé est un anticorps anti-méthylcytosine.
3. Procédé selon la revendication 1 ou 2, dans lequel l'échantillon biologique est du sang, un fluide corporel, du sérum, du plasma, un lysat cellulaire, ou un lysat tissulaire d'un mammifère.
4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel l'échantillon d'ADN dérivé de l'ADN génomique contenu dans l'échantillon biologique est un échantillon d'ADN digéré au préalable par une enzyme de restriction pour laquelle un site de clivage de reconnaissance n'est pas présent dans la région d'ADN cible de l'ADN génomique, ou un échantillon d'ADN purifié au préalable.
5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel l'enzyme de restriction sensible à la méthylation est HhaI.
6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel un contre-oligonucléotide est ajouté lors de la séparation de l'ADN double brin méthylé en l'ADN simple brin méthylé au cours de la deuxième étape.

Fig.1




Fig.2





Fig.3



MK MD D MC C MB B MA A

Fig.4



MK MD D MC C MB B MA A

Fig. 5



MK MD D MC C MB B MA A

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2007081791 A [0004]
- JP 09725639 B [0197]
- JP 2008077967 A [0197]

Non-patent literature cited in the description

- *Nucleic Acids Res.*, 11 August 1994, vol. 22 (15), 2990-7 [0002]
- *Proc. Natl. Acad. Sci. U.S.A.*, 18 March 1997, vol. 94 (6), 2284-9 [0002]
- **GRUENBAUM et al.** *Nucleic Acid Research*, vol. 9, 2509-2515 [0042]
- *Methods in Yeast Genetics*. Cold Spring Harbor Laboratory [0148] [0175]

专利名称(译)	测定DNA甲基化的方法		
公开(公告)号	EP2272975B1	公开(公告)日	2015-04-22
申请号	EP2009725639	申请日	2009-03-25
[标]申请(专利权)人(译)	住友化学有限公司		
申请(专利权)人(译)	住友化学公司		
当前申请(专利权)人(译)	住友化学公司		
[标]发明人	TOMIGAHARA YOSHITAKA SATO H HIDEO TARUI HIROKAZU		
发明人	TOMIGAHARA, YOSHITAKA SATO H, HIDEO TARUI, HIROKAZU		
IPC分类号	C12Q1/68 C12N15/09 G01N33/53		
CPC分类号	G01N33/6854 C12Q1/683 C12Q1/6851 G01N33/5308 G01N2333/922 G01N2440/12		
优先权	2008077967 2008-03-25 JP		
其他公开文献	EP2272975A4 EP2272975A1		
外部链接	Espacenet		

摘要(译)

本发明涉及测量生物样本中包含的基因组DNA中的目标DNA区域中甲基化DNA含量的方法，等等。

5'

GTGGCCACTGCGGAGTCGNGGTTGGGCGCCGACCTACAGNGCCGNGNGCCGTGA

GCCTGGCCGTGTGGGATCGTCACACTCGTCGTC-3' (SEQ ID NO: 17)